healthevidencedigest

Blog

  • Asthma Patients Across the U.S. Have Been Rationing Inhalers Because They Could Not Afford Them. Two Generic Approvals Just Changed That.

    Asthma Patients Across the U.S. Have Been Rationing Inhalers Because They Could Not Afford Them. Two Generic Approvals Just Changed That.

    The essentials: two inhaler generic approvals Generic Flovent HFA (fluticasone propionate 44 mcg per actuation, Glenmark Specialty SA): FDA approved March 3, 2026. First true generic equivalent of Flovent HFA. Controller inhaler for maintenance treatment of asthma in adults and pediatric patients aged 4 and older. GSK discontinued brand-name Flovent in December 2023; authorized generics that replaced it triggered insurance coverage and pricing problems that caused patients, particularly children and Medicaid patients, to stop taking their controller medication. Glenmark received a Competitive Generic Therapy (CGT) designation with 180 days of market exclusivity. Flovent HFA 44 mcg had approximately $520 million in annual U.S. sales. Generic Ventolin HFA (albuterol sulfate 90 mcg per actuation, Cipla USA): FDA approved April 22, 2026. First AB-rated generic equivalent of Ventolin HFA (GlaxoSmithKline). Rescue inhaler for treatment or prevention of bronchospasm in patients aged 4 and older, and for prevention of exercise-induced bronchospasm. The U.S. albuterol market is valued at approximately $1.5 billion. Manufactured at Cipla’s dedicated inhalation facility in Fall River, Massachusetts. What this means for patients: these are the same drugs in the same devices. The generics have been demonstrated bioequivalent and therapeutically equivalent to the brand-name products. If your pharmacist substitutes either generic at the counter, the clinical effect is identical.

    Asthma affects approximately 25 million Americans, including 4.6 million children. It kills an estimated 3,500 people in the United States each year. Most of those deaths are preventable with appropriate medication. And a significant proportion of Americans with asthma are not taking their medication as prescribed, not because they do not want to, but because they cannot afford it.

    The two most essential classes of asthma medication, a daily inhaled corticosteroid (ICS) controller to prevent inflammation and attacks, and a short-acting beta2-agonist (SABA) rescue inhaler for acute bronchospasm, have spent the past decade as some of the most expensive everyday medications in the American pharmacy. A Ventolin HFA inhaler without insurance has historically run $50 to $80 per canister. A Flovent HFA 44 mcg inhaler has cost $200 or more per month out of pocket. For patients who need both and lack adequate insurance coverage, the inhaler bill can exceed $3,000 per year for what should be standard, widely accessible management of a common chronic condition.

    Between March and April 2026, the FDA approved the first true generics for both inhalers. This post covers why inhaler generics have been so slow to arrive, why the Flovent situation is more complicated than it first appears, what these approvals mean practically for patients and prescribers, and why the path from approval to affordability is not as automatic as it should be.

    Why Asthma and Why These Two Inhalers

    The disease

    Asthma is a chronic inflammatory disease of the airways characterized by variable airflow obstruction, bronchial hyperresponsiveness, and underlying airway inflammation. In susceptible individuals, airways become swollen, narrowed, and clogged with mucus in response to triggers including allergens, exercise, cold air, respiratory infections, pollution, and emotional stress.

    Between 5 and 10% of Americans have an asthma diagnosis, with higher prevalence in low-income communities, communities of color, and urban environments with elevated air pollution. Asthma disproportionately affects Black and Puerto Rican Americans, who have higher hospitalization and death rates than white Americans with asthma, a disparity driven by a combination of environmental exposures, healthcare access barriers, and medication affordability.

    Why two inhalers are needed: the controller-rescue distinction

    The standard two-drug approach to asthma management reflects two distinct clinical needs:

    The controller inhaler (inhaled corticosteroid, ICS): taken daily whether or not symptoms are present. Fluticasone propionate (Flovent) is an ICS that suppresses the chronic airway inflammation underlying asthma, reducing the frequency and severity of attacks over time. ICS therapy is the most effective long-term preventive treatment for persistent asthma and is recommended for all but the mildest cases by major asthma guidelines. When taken consistently, ICS reduces asthma hospitalizations, emergency department visits, and deaths. When stopped, airway inflammation returns, attacks become more frequent, and outcomes worsen.

    The rescue inhaler (short-acting beta2-agonist, SABA): used during or immediately before an attack or exercise-induced symptoms. Albuterol (Ventolin, Proventil) relaxes the smooth muscle around the airways within minutes, producing rapid bronchodilation that relieves acute bronchospasm. It is the cornerstone of acute symptom management.

    The distinction matters for the generic story: the controller inhaler is a daily maintenance medication where consistent, affordable access directly prevents hospitalizations. The rescue inhaler is an emergency tool where access failures can be immediately life-threatening.

    The Flovent Discontinuation Disaster: Why a Generic Was Urgently Needed

    The generic fluticasone propionate story is not simply a matter of patent expiration and market entry. There is a specific policy failure in the background that makes the Glenmark approval more urgent.

    In December 2023, GlaxoSmithKline discontinued Flovent HFA and Flovent Diskus, citing an Inflation Reduction Act provision that would have required GSK to pay rebates on pediatric medicines classified as “small molecule” drugs. Rather than pay those rebates, GSK discontinued the branded product and replaced it with so-called “authorized generic” versions, essentially the same drug under a different commercial arrangement, sold through a partnership with Prasco.

    The authorized generic distinction matters because of how drug formularies work. Authorized generics are not subject to the same FDA bioequivalence approval process as true generics; they are sold by the brand manufacturer or its licensee under the same NDA as the brand. Because they do not go through the standard generic approval pathway, they are often not placed on generic formulary tiers by pharmacy benefit managers. In many insurance plans, the authorized generic fluticasone ended up at a higher copay tier than the brand-name Flovent had been, because brand-name formulary positioning depends on rebate negotiations that the authorized generic was not structured to provide.

    The result was that many patients found their affordable Flovent suddenly replaced by a technically identical drug at a higher out-of-pocket cost. A 2025 published study found that children stopped using inhaled corticosteroids after Flovent was discontinued, particularly children on Medicaid, increasing their risk of asthma attacks.

    This is the public health context for the Glenmark approval. The FDA’s own statement at the time of approval specifically noted the access problem: Acting CDER Director Tracy Beth Høeg stated that the agency anticipated that the first true generic would bring “increased availability and reduced costs” specifically because a true generic approved through the standard ANDA pathway is subject to the same formulary positioning as other generics.

    The authorized generic vs. true generic distinction: why it matters for your wallet When a brand-name drug is discontinued and replaced by an authorized generic, insurance formulary tiers do not automatically reclassify it as a low-cost generic. This is because formulary tier placement is negotiated between pharmacy benefit managers and drug manufacturers based on rebates. Authorized generics made by the original manufacturer are often not competitive on rebates with true generics manufactured independently. When a true generic receives FDA approval through the ANDA pathway, it enters the generic formulary tier automatically, and pharmacists can substitute it for any prescription written for the brand-name drug. This is the mechanism that drives real price competition. Glenmark’s fluticasone propionate, having received FDA approval through the standard process, is now positioned to be placed on generic formulary tiers by insurers, which is what will determine whether patients see lower copays.

    Why Inhaler Generics Take So Much Longer Than Pill Generics

    Albuterol and fluticasone are not new molecules. Albuterol has been used in medicine since the 1960s. Fluticasone has been on the market since 1994. Their small-molecule drug patents expired long ago. And yet first generic inhalers for Ventolin HFA took until 2026 and for Flovent HFA until 2026. Why?

    The answer is in the delivery system. An inhaled aerosol is not just the drug; it is the combination of drug, propellant, and device. When the pharmaceutical industry transitioned from chlorofluorocarbon (CFC) propellants to hydrofluoroalkane (HFA) propellants in the early 2000s following the Montreal Protocol on ozone-depleting substances, every inhaler essentially became a new drug-device combination. And drug-device combinations, unlike simple tablets or solutions, are substantially harder to demonstrate bioequivalent.

    For an inhaled aerosol to be AB-rated (substitutable at the pharmacy), the FDA requires demonstrating that the generic delivers the same drug dose to the same location in the lung as the brand-name product. This requires showing pharmacokinetic equivalence (that the same amount of drug enters the bloodstream), and in vitro aerosol performance equivalence (that the particle size distribution, delivered dose, and inhaler performance match). The manufacturing precision required to produce a metered-dose inhaler that consistently delivers the correct dose in the correct particle size is considerably more demanding than manufacturing a tablet.

    This regulatory and manufacturing complexity created a long gap between small-molecule patent expiry and actual generic availability for HFA inhalers. Cipla’s approval as the first AB-rated Ventolin generic, manufactured at a new dedicated inhalation facility in Fall River, Massachusetts, reflects years of investment in that specialized manufacturing capability.

    What Patients and Prescribers Should Know

    Generic fluticasone propionate HFA (Glenmark): for daily asthma control

    What it is and who it is for: A maintenance inhaled corticosteroid for adults and children aged 4 and older with asthma requiring daily preventive therapy. It is identical in drug, dose, and expected clinical effect to Flovent HFA 44 mcg.

    How to use it: Two inhalations twice daily, morning and evening. Rinse your mouth with water and spit after each use without swallowing. This is the single most important adherence step for ICS inhalers, reducing the risk of oropharyngeal candidiasis (oral thrush), a well-known and entirely preventable complication of inhaled corticosteroid use. Many patients skip the rinse and experience oral thrush unnecessarily.

    What it does not do: It is not a rescue inhaler and will not relieve an acute asthma attack. Always carry a separate rescue inhaler (albuterol) and use the controller inhaler consistently even on days without symptoms.

    Contraindicated for: Primary treatment of status asthmaticus or acute asthma attacks requiring intensive measures. Patients with hypersensitivity to fluticasone propionate or any component of the formulation.

    Common adverse effects: Oropharyngeal candidiasis (thrush), hoarseness, immunosuppression effects with long-term high-dose use, slowed growth in children (with long-term use at higher doses, though this effect has been assessed as clinically small relative to the benefit of adequate asthma control).

    Generic albuterol sulfate HFA (Cipla): the rescue inhaler

    What it is and who it is for: A short-acting beta2-agonist (SABA) for relief of acute bronchospasm and prevention of exercise-induced bronchospasm in adults and children aged 4 and older. It is the rescue inhaler: use it when symptoms occur or are about to occur, not as a daily maintenance therapy.

    How to use it: 2 puffs every 4 to 6 hours as needed for bronchospasm. For prevention of exercise-induced bronchospasm: 2 puffs 15 to 30 minutes before exercise. Shake before each use. If using more than twice a week for symptom relief (excluding pre-exercise use), this is a signal that asthma is not adequately controlled on current therapy and that the prescribing clinician should review the management plan.

    Contraindicated for: Hypersensitivity to albuterol.

    Common adverse effects: Tremor, palpitations, tachycardia, headache, dizziness, throat irritation. Most adverse effects are mild and transient at recommended doses.

    The Bigger Picture: The Inhaler Cost Problem in American Asthma Care

    The arrival of these generics is a meaningful improvement in access. It is not a complete solution.

    The United States has the highest asthma medication costs of any high-income country. American patients pay up to 10 times more for asthma inhalers than patients in comparable countries. A Ventolin HFA that costs $50 without insurance in the U.S. costs under $10 in Canada, France, or the United Kingdom. The gap is driven by a combination of patent protection on drug-device combinations, lack of government price negotiation authority, and the rebate structure of the pharmacy benefit management system.

    The consequences are documented and serious. Studies consistently show that a substantial proportion of U.S. asthma patients report rationing medication due to cost, including cutting back on daily controller therapy and relying more heavily on rescue inhalers. This pattern, using rescue inhalers more and controller inhalers less, is associated with worse asthma control, more frequent attacks, and higher hospitalization rates. In a 2023 analysis, cost-related asthma medication adherence problems were most pronounced in uninsured patients, Medicaid patients, and patients in Southern states with lower Medicaid expansion uptake.

    Generic entry begins to address this. The market for Flovent HFA 44 mcg is significant, with annual sales in the U.S. estimated at about $520 million, highlighting both the clinical importance of the medication and the potential impact of the generic entrant on pricing and access. The total U.S. albuterol market is valued at approximately $1.5 billion, per February 2026 IQVIA data. Both of these markets have been essentially brand-name only for years. Generic competition in both simultaneously, for the first time, represents a structural shift in access.

    For patients, the practical question is not list price but formulary tier and out-of-pocket cost. As insurers and pharmacy benefit managers update their formularies to include the new generics, patients who previously paid high copays for brand-name or authorized generic inhalers should see reductions. This process takes weeks to months depending on the plan and the formulary update cycle.

    Resources for Patients Who Cannot Afford Asthma Inhalers Now

    For patients who need affordable asthma inhalers immediately, before insurance formulary changes take effect:

    • GoodRx: provides real-time pricing comparisons for albuterol and fluticasone at pharmacies near you. GoodRx discount cards often bring the cash price of generics below the insured copay for some plans.
    • NeedyMeds: database of patient assistance programs and lower-cost options for asthma medications.
    • Asthma and Allergy Foundation of America: maintains current information on asthma medication assistance programs and treatment resources.
    • GSK patient assistance programs: for patients who still need Flovent authorized generics, GSK has patient support resources.
    • Mark Cuban’s Cost Plus Drugs: lists fluticasone and albuterol generics at significant discounts compared to retail pharmacy cash prices.

    For related HED coverage of medication access and the gap between approval and affordability in other drug classes, see our post on PONLIMSI and why 19 denosumab biosimilar approvals have not produced the price reductions patients expected, and our post on Langlara and interchangeable insulin biosimilar approvals, where the same structural issues between approval and real-world affordability play out.

    Sources

    FDA generic Flovent HFA announcement: FDA approves first generic of Flovent HFA for treatment of asthma. FDA.gov. March 3, 2026.

    Cipla generic Ventolin HFA press release: Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA. PRNewswire. April 23, 2026.

    AJMC Flovent generic coverage: FDA Approves First Generic Fluticasone Propionate Inhaler, Boosting Affordable Asthma Care. ajmc.com. March 2026.

    Pulmonology Advisor Flovent generic coverage: Glenmark to Launch First Generic Version of Flovent HFA. pulmonologyadvisor.com. March 2026.

    Medscape generic Flovent clinical review: Generic Flovent Approval Expands Options for Asthma. medscape.com. March 9, 2026.

    Allergy and Asthma Network Flovent background: New Generic Replaces Discontinued Flovent. allergyasthmanetwork.org. March 2026.

    Managed Healthcare Executive Flovent access analysis: FDA approves first generic of Flovent for asthma. managedhealthcareexecutive.com. March 2026.

    Drug Store News albuterol market data: Cipla receives FDA nod for first generic Ventolin HFA. drugstorenews.com. April 2026.

    BioSpace Cipla coverage: Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin HFA. biospace.com. April 2026.

    Contract Pharma Glenmark coverage: Glenmark Gets FDA Nod for Fluticasone Propionate Inhalation Generic. contractpharma.com. March 2026.

    NHLBI asthma overview: Asthma. NHLBI.

    CDC asthma data: Asthma Surveillance Data. cdc.gov.

    Asthma StatPearls: Asthma. StatPearls. NCBI.

    Fluticasone StatPearls: Fluticasone. StatPearls. NCBI.

    Inhaler cost disparity research: Comparison of Asthma Medication Prices in the US versus Other Countries. PMC6996413.

    Montreal Protocol and HFA transition: Montreal Protocol on Substances That Deplete the Ozone Layer. EPA.gov.

    Authorized generics explained: Authorized Generic Drugs. FDA.gov.

    Patient resources: Asthma and Allergy Foundation of America | GoodRx inhaler pricing | NeedyMeds | Cost Plus Drugs | NHLBI Asthma Action Plan

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Asthma management should be overseen by a qualified healthcare provider. Do not change your inhaler regimen without consulting your prescribing clinician. If your pharmacist substitutes a generic inhaler, confirm the substitution with your provider at your next visit if you have any questions about device technique.
  • Immunotherapy Stopped Working. A New Drug Is Teaching Cancer Cells to Stop Hiding. Here Is What the EMITT-1 Trial Data Shows.

    Immunotherapy Stopped Working. A New Drug Is Teaching Cancer Cells to Stop Hiding. Here Is What the EMITT-1 Trial Data Shows.

    What this post covers: This is a pipeline post covering early-phase clinical trial data, not an FDA approval. GRWD5769 is investigational: it is not approved for any indication and is not available outside of clinical trials. This post covers Phase 1b data presented at the ASCO 2026 Annual Meeting in an oral session on June 2, 2026. The company: Greywolf Therapeutics, a clinical-stage biotech headquartered in Oxford, UK. The drug: GRWD5769, the world’s first oral inhibitor of ERAP1 (Endoplasmic Reticulum Aminopeptidase 1), a first-in-class mechanism that has never been clinically validated before. The trial: EMITT-1 (NCT06923761), Phase 1b expansion cohorts across 28 centers in Australia, France, Spain, and the United Kingdom. Who was enrolled: patients with six types of advanced solid tumors (lung, liver, bladder, cervical, head and neck, colorectal) who had already developed secondary resistance to prior anti-PD-1 immunotherapy, or microsatellite stable colorectal cancer where checkpoint inhibitors are not effective. These are among the hardest-to-treat populations in oncology. What the data showed: objective response rates of 13 to 36% across all six cohorts; durable clinical benefit rates of 18 to 55%; progression-free survival of 33 weeks in lung cancer and colorectal cancer cohorts; no safety signals at the doses studied. What comes next: Stage 2 cohort expansions are underway to inform a planned randomized Phase 2 study.

    There is a fundamental problem at the heart of cancer immunotherapy. The immune system works by recognizing abnormal cells as foreign and destroying them. T cells learn to do this by reading the proteins displayed on cell surfaces, antigens that signal “I am not normal.” Cancer immunotherapy, in particular checkpoint inhibitors like the PD-1 drugs that transformed oncology in the 2010s, works by releasing the brakes on T cells so they can attack the cancer they can see.

    The problem is that cancer can learn to hide. In a substantial proportion of patients, particularly those whose tumors initially responded to PD-1 inhibition and then progressed, the cancer has found ways to alter or reduce the antigens on its surface, essentially making its cells harder for the immune system to recognize. The T cells that were attacking the cancer are no longer fully activated because the targets they were looking for have changed or disappeared.

    This is called secondary anti-PD-1 resistance, and it is one of the most consequential unsolved problems in cancer medicine. For the 30 to 40% of patients who achieve initial benefit from checkpoint inhibitors and then progress, there has been no approved targeted approach to restore immune recognition.

    Greywolf Therapeutics, an Oxford-based clinical-stage biotech, has been building toward a mechanistically novel answer: target the enzyme that cancer cells use to edit their surface proteins and alter what the immune system sees. At the 2026 ASCO Annual Meeting, they presented the first clinical evidence that this approach works in human patients.

    What ERAP1 Is and Why Cancer Uses It to Hide

    To understand why ERAP1 inhibition is a new and compelling idea, it helps to understand how cells normally present antigens to the immune system.

    Every nucleated cell in the body continuously samples its own intracellular protein content, breaking proteins into short peptide fragments and displaying them on the cell surface via MHC class I (major histocompatibility complex class I) molecules. Cytotoxic T cells patrol for these displayed peptides, looking for fragments that look foreign, viral, bacterial, or the products of oncogenic mutations. When a T cell recognizes a foreign peptide on an MHC-I molecule, it activates and kills the cell displaying it.

    The quality and composition of the peptide fragments displayed on MHC-I, collectively called the immunopeptidome, depends critically on which peptides get trimmed to the right length and structure inside the cell. This trimming is performed primarily by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1), an enzyme in the endoplasmic reticulum that trims precursor peptides before they are loaded onto MHC-I for surface display.

    ERAP1 is therefore a gatekeeper of antigen presentation. It determines which peptide fragments make it to the cell surface and get displayed to T cells. In many cancers, ERAP1 activity or expression is altered in ways that shift the immunopeptidome toward a less immunogenic profile, reducing the display of peptides that T cells could recognize as foreign. This is one of the mechanisms by which cancers can reduce their immunogenicity over time, evading the T cell attacks that checkpoint inhibitor therapy is trying to mount.

    By inhibiting ERAP1, the hypothesis is that you can alter the cancer cell’s antigen presentation, shifting the immunopeptidome back toward a more immunogenic profile, effectively making the cancer visible again to T cells that had become ineffective because their targets were hidden or reduced.

    The cycling dosing strategy: why Greywolf uses an on-off schedule GRWD5769 is not taken continuously. It is administered on a cyclical Q3W (every 3 weeks) on-off schedule in the EMITT-1 trial. This design reflects an important scientific principle: if you continuously inhibit ERAP1 and lock the immunopeptidome into one new configuration, T cells will adapt to that new configuration and may eventually become tolerant to it, producing a new form of exhaustion. By cycling on and off, the drug alternates between two different antigenic repertoires, the ERAP1-active state and the ERAP1-inhibited state, effectively generating a broader range of tumor antigens for T cells to respond to over time. This dynamic approach to antigen presentation is designed to generate more diverse T cell responses and to prevent the chronic antigen exposure that leads to T cell exhaustion, one of the fundamental drivers of immunotherapy resistance.

    The EMITT-1 Trial: Design and Patient Population

    EMITT-1 (NCT06923761) is an adaptive Phase 1/2 global study evaluating GRWD5769 in combination with cemiplimab (Libtayo, Regeneron/Sanofi), an approved anti-PD-1 checkpoint inhibitor. The trial is ongoing at 28 centers across Australia, France, Spain, and the United Kingdom.

    The Phase 1b expansion cohorts were designed to enroll patients with specific tumor types and a shared defining characteristic: most had documented secondary resistance to prior anti-PD-1 therapy. These patients had received checkpoint inhibitors, achieved some benefit, and then had their disease progress. For patients in the microsatellite stable colorectal cancer (MSS-CRC) cohort, no prior PD-1 therapy was required because checkpoint inhibitors are not licensed for this indication and are generally ineffective; this represents a population where immunotherapy has never worked.

    Six tumor types enrolled:

    • Non-small cell lung cancer (NSCLC)
    • Urothelial carcinoma (UC, bladder cancer)
    • Hepatocellular carcinoma (HCC, liver cancer)
    • Microsatellite stable colorectal cancer without liver metastases (MSS-CRC NLM)
    • Squamous cell carcinoma of the head and neck (SCCHN)
    • Cervical cancer

    Patients had a median of 2 prior lines of therapy, confirming this is a heavily pretreated population. 14 evaluable patients were enrolled in five cohorts; 12 were enrolled in the MSS-CRC cohort. The principal investigator is Professor Fiona Thistlethwaite, Consultant Medical Oncologist and Medical Director of the NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust.

    The ASCO 2026 Data: What Every Cohort Showed

    The data table below comes directly from the Greywolf Therapeutics press release accompanying the oral session presentation at ASCO 2026 (Abstract 2500):

    Tumor typeEvaluable patientsPartial responsesORRDurable clinical benefit (DCB ≥6 months)Median PFS
    Urothelial carcinoma (bladder)14536%36%8 weeks
    Non-small cell lung cancer14321%55%33 weeks
    Hepatocellular carcinoma (liver)14214%32%16 weeks
    MSS colorectal cancer (no liver mets)12217%51%33 weeks
    Cervical cancer14214%18%9 weeks
    Head and neck squamous cell carcinoma8113%38%14 weeks

    Source: Greywolf Therapeutics ASCO 2026 press release. GlobeNewswire. June 2, 2026. Median follow-up: 8.8 months; data still maturing.

    The ORR findings

    The objective response rates of 13 to 36% may not look dramatic in absolute terms, but they need to be evaluated against the baseline. These are patients who have already failed anti-PD-1 therapy. When a patient has secondary resistance to a PD-1 inhibitor and is given the same PD-1 inhibitor again, the expected response rate is generally below 5%. Achieving 21% in lung cancer and 36% in bladder cancer in this population represents a meaningful signal that the combination is restoring immune activity against tumors that had become resistant to the mechanism.

    The urothelial carcinoma ORR of 36% is the highest single-cohort response rate and is striking in a disease where second-line options after checkpoint inhibitor failure are limited.

    The durable clinical benefit findings: the most important numbers

    The durable clinical benefit (DCB) rate, defined as complete response, partial response, or stable disease lasting at least 6 months, is arguably the more clinically meaningful metric in a Phase 1b setting. It captures patients who are deriving sustained benefit from the treatment, not just those who had a measurable tumor reduction.

    A 55% DCB rate in NSCLC patients with secondary anti-PD-1 resistance means more than half of evaluable lung cancer patients remained progression-free or showed response for at least 6 months. In a setting where treatment options are limited and durable benefit is, in Professor Thistlethwaite’s words, “exceptionally rare,” that is a clinically compelling signal.

    The 51% DCB in MSS-CRC is notable for a different reason: microsatellite stable colorectal cancer is one of the cancers most resistant to immunotherapy. Checkpoint inhibitors do not work in this population at standard doses, and the failure of multiple combination approaches in this setting has been a persistent frustration in colorectal cancer oncology. Any 6-month durable benefit rate above 30 to 40% in MSS-CRC is worth attention.

    The PFS findings: durability context

    The 33-week (approximately 8-month) median PFS in both NSCLC and MSS-CRC cohorts, with follow-up still maturing at 8.8 months, means that at the time of data cutoff, a substantial number of patients were still on treatment and progression-free. This is not a signal of rapid early responses that quickly relapse; it is a signal of sustained disease control in patients who had already exhausted prior options.

    What Makes This Mechanism Genuinely New

    The immunotherapy field has spent a decade trying to address anti-PD-1 resistance, and most approaches have targeted the same immune checkpoint axes (CTLA-4, LAG-3, TIM-3, TIGIT) or have tried combination chemotherapy-immunotherapy approaches. These have had variable and generally modest success in the secondary resistance setting.

    ERAP1 inhibition targets a completely different step in the immunological chain, not the T cell inhibitory signaling that checkpoint inhibitors address, but the upstream process by which the cancer cell prepares and displays the antigens that T cells are supposed to respond to. This is a mechanistically orthogonal approach: rather than removing a brake on T cells, it changes what T cells can see.

    The clinical proof-of-mechanism from ASCO 2024 was the first demonstration that a small molecule could pharmacologically modulate the human immunopeptidome in cancer patients. The ASCO 2026 Phase 1b data shows that this modulation, in combination with continued PD-1 blockade, translates into clinical responses and durable disease control in patients who were no longer responding to PD-1 blockade alone.

    The combination logic is coherent: re-expose the immune system to a new or altered antigenic repertoire (via ERAP1 inhibition), then allow checkpoint inhibitor therapy to act on the reinvigorated T cell response. The cycling on-off schedule is designed to prevent the new antigenic landscape from itself becoming the source of a new tolerance pattern.

    The Safety Signal: Why It Matters at Phase 1b

    One of the more notable aspects of the EMITT-1 data is the safety profile. Most adverse events were Grade 1, and no safety signals were identified. This is a Phase 1b combination of a first-in-class oral drug with an approved anti-PD-1 antibody in heavily pretreated cancer patients. The absence of cumulative or overlapping toxicity at efficacious doses is not guaranteed and is practically important: it enables patients to remain on treatment for extended periods, which is what produces the durable disease control signals observed.

    The tolerability advantage of an oral delivery mechanism for the ERAP1 inhibitor component, rather than a second intravenous biologic, is also relevant for real-world treatment burden.

    What Comes Next

    Greywolf has stated that the trial is now advancing into Stage 2 cohort expansions to inform a randomized Phase 2 study. The NSCLC and MSS-CRC cohorts, given their durable clinical benefit signals, are likely to be priority tumor types for expansion and for the Phase 2 design.

    The path from Phase 1b to Phase 2 to potential FDA review is measured in years, not months. For the NSCLC setting, which is by far the largest and most commercially significant of the six cohorts, a Phase 2 study with appropriate endpoints (PFS, OS, or biomarker-confirmed ORR) would be required before any regulatory filing could be contemplated. For MSS-CRC, where there are genuinely no effective immunotherapy options and the unmet need is acute, the FDA’s accelerated approval pathway for drugs in serious conditions without adequate alternatives could potentially provide a more compressed timeline if Phase 2 data are compelling.

    What EMITT-1 has done is validate the target. ERAP1 inhibition, long recognized as mechanistically compelling in preclinical models, has now produced clinical proof-of-mechanism and Phase 1b efficacy signals across six tumor types. That validation is what enables the field to invest confidently in the next round of trials.

    What This Means for Patients With Immunotherapy-Resistant Cancers

    For patients with advanced solid tumors who have already received and progressed on PD-1 inhibitor therapy, GRWD5769 is not yet available outside of clinical trials. The EMITT-1 trial continues to enroll across its centers in Australia, France, Spain, and the United Kingdom.

    Patients and oncologists who are interested in EMITT-1 enrollment eligibility can check ClinicalTrials.gov (NCT06923761) for current enrollment status and site information. Access to trials at UK centers (notably The Christie in Manchester) or the European sites listed may be relevant for international patients. The Greywolf Therapeutics website at gwt.bio provides additional contact information for clinical trial inquiries.

    For patients with MSS-CRC specifically: this is a population with very limited immunotherapy options and where multiple prior combination trials have failed to produce meaningful benefit. The Phase 1b signal in this cohort is the most scientifically surprising finding in the dataset and is likely to generate significant interest from the colorectal oncology community in the Stage 2 expansion.

    For related HED coverage of other immunotherapy advances in 2026, see our post on the RP1 (vusolimogene oderparepvec) Complete Response Letter and what the FDA’s evidence standards require for oncolytic immunotherapy approval and our post on Lifyorli (relacorilant) and the novel mechanism of addressing cortisol-mediated chemotherapy resistance in platinum-resistant ovarian cancer.

    Sources

    Greywolf Therapeutics ASCO 2026 press release (primary source): Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types. GlobeNewswire. June 2, 2026.

    BioSpace press release: Greywolf Therapeutics reports durable clinical responses with first-in-class oral ERAP1 inhibitor GRWD5769 across six solid tumor types. biospace.com. June 2, 2026.

    European Biotechnology Magazine independent analysis: Greywolf reports early responses with oral ERAP1 inhibitor in solid tumours. european-biotechnology.com. June 2026.

    ASCO 2024 proof-of-mechanism press release: Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769 at ASCO 2024. PRNewswire. June 3, 2024.

    EMITT-1 trial registration: NCT06923761. ClinicalTrials.gov.

    ASCO 2026 Annual Meeting: ASCO Annual Meeting 2026. asco.org.

    ERAP1 biology and immunopeptidome: ERAP1 in antigen presentation. PMC7027234.

    MHC class I antigen presentation: MHC Class I. StatPearls. NCBI.

    Cemiplimab (Libtayo) FDA approvals: Cemiplimab approved indications. FDA.gov.

    Greywolf Therapeutics: gwt.bio.

    Disclaimer: Health Evidence Digest provides general information about clinical research and pipeline developments for educational purposes. This content is not a substitute for professional medical advice. GRWD5769 is an investigational drug and is not FDA-approved for any indication. The Phase 1b data presented here represents early-stage evidence; much larger randomized trials are required before any conclusions about efficacy and safety can be drawn for broad clinical use. Patients interested in clinical trial participation should consult with their oncologist and review current eligibility information at ClinicalTrials.gov.

  • Venetoclax Has Transformed Blood Cancer Treatment for Nearly a Decade. A Generic Version Just Became Available for the First Time. Here Is What Patients With CLL and AML Need to Know.

    Venetoclax Has Transformed Blood Cancer Treatment for Nearly a Decade. A Generic Version Just Became Available for the First Time. Here Is What Patients With CLL and AML Need to Know.

    The essentials: On May 15, 2026, the FDA approved venetoclax tablets (Dr. Reddy’s Laboratories) in three strengths, 10 mg, 50 mg, and 100 mg, as the first generic version of Venclexta (venetoclax, AbbVie/Genentech). Venclexta has been on the market since April 2016 and at its brand list price costs thousands of dollars per month, making it inaccessible or unaffordable for many patients who need it. The generic is therapeutically equivalent to the brand-name product: the same molecule, the same doses, the same clinical indications. What venetoclax is approved for: adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including as part of multiple combination regimens, and adults with newly diagnosed AML who are 75 years or older or have comorbidities precluding intensive chemotherapy, in combination with azacitidine, decitabine, or low-dose cytarabine. Recent additional approval: in February 2026, the FDA also approved venetoclax plus acalabrutinib as the first all-oral, fixed-duration combination for previously untreated CLL. What the generic approval means in practice: competition between generic and brand-name manufacturers typically drives price reduction over time. How quickly and how substantially prices fall depends on how many generic manufacturers enter the market and on formulary and pharmacy benefit manager decisions. For patients currently on Venclexta: your pharmacist may substitute the generic at the counter; check with your oncologist and pharmacist about what to expect at your next fill. For patients considering venetoclax therapy: the generic approval is the beginning of an access improvement story; real-world pricing at pharmacies will emerge over the coming weeks and months.

    Few drugs in the history of blood cancer treatment have had as broad and rapid an impact as venetoclax. When the FDA first approved it in April 2016, it validated a decade of research into BCL-2 (B-cell lymphoma-2) as a cancer survival target and introduced a mechanism of action, apoptosis restoration, that was entirely distinct from chemotherapy or the kinase inhibitors that preceded it in the same patient populations.

    In the nearly decade since, venetoclax has accumulated FDA approvals across multiple blood cancer indications, generated pivotal trial data with some of the most compelling remission rates ever seen in chronic lymphocytic leukemia and AML, and become a cornerstone of treatment regimens ranging from CLL to multiple myeloma to myelodysplastic syndromes. It is taken by hundreds of thousands of patients. And until May 15, 2026, every one of them required a brand-name drug at brand-name pricing.

    On May 15, 2026, Dr. Reddy’s Laboratories received the first FDA generic approval for venetoclax, ending the brand exclusivity that AbbVie and Genentech have held since 2016. For a drug with a monthly list price that has historically exceeded $10,000, the arrival of generic competition is a meaningful moment for patients and payers.

    This post covers what venetoclax is, the science behind why it works, its complete approved indication landscape, the safety profile clinicians and patients need to understand, and what the generic approval means practically.

    What BCL-2 Is and Why Blocking It Kills Cancer Cells

    Understanding venetoclax requires understanding a fundamental principle of cancer biology: cancer cells have learned to cheat death.

    Normal cells have a built-in self-destruction mechanism called apoptosis, programmed cell death. When a cell is damaged, mutated, or simply no longer needed, internal signaling pathways trigger a cascade that dismantles the cell from within. This mechanism is one of the body’s primary defenses against cancer: cells that accumulate oncogenic mutations are normally eliminated by apoptosis before they can proliferate into a tumor.

    Many cancer cells, particularly blood cancers including CLL, SLL, AML, and multiple myeloma, escape this mechanism by overexpressing BCL-2, a protein that resides on the outer membrane of mitochondria and functions as a survival signal. BCL-2 works by binding and sequestering BH3-only proteins, the molecules that would normally activate the apoptotic cascade. By flooding the cell with BCL-2, cancer cells effectively disable their own self-destruct mechanism, allowing them to accumulate, resist chemotherapy, and evade the immune system.

    Venetoclax is an oral, highly selective BCL-2 inhibitor. It was discovered through a collaboration between AbbVie and Genentech using fragment-based drug design, specifically engineered to mimic the BH3 domain of pro-apoptotic proteins. By binding to BCL-2 with extremely high affinity, venetoclax displaces the sequestered BH3-only proteins, freeing them to activate the mitochondrial apoptotic pathway. The result is rapid apoptotic cell death, within hours of exposure in susceptible cells, in cancer cells that have been surviving by BCL-2-mediated cheating.

    Why BCL-2 inhibition produces tumor lysis syndrome (TLS): the critical safety concept Venetoclax works so effectively, and so rapidly, in BCL-2-dependent cancer cells that its primary serious risk is a direct consequence of its efficacy. When large numbers of cancer cells die rapidly, they release their intracellular contents, including potassium, phosphate, uric acid, and other electrolytes, into the bloodstream simultaneously. This electrolyte release is called tumor lysis syndrome (TLS). Severe TLS can cause dangerous elevations in potassium (leading to fatal cardiac arrhythmias), elevated phosphate (causing calcium to drop, risking seizures and cardiac dysfunction), elevated uric acid (causing kidney damage), and acute kidney failure. This is why venetoclax requires a careful ramp-up dosing schedule rather than starting at the full therapeutic dose. The ramp-up, beginning at 20 mg daily and escalating weekly over 5 weeks to 400 mg in CLL, is specifically designed to kill cancer cells gradually enough to allow the kidneys and other organs to clear the cellular debris without being overwhelmed. Pre-treatment assessment of TLS risk is mandatory. Patients at high risk (large lymph nodes, high lymphocyte counts) require hospitalization and intravenous hydration for at least the first dose of each ramp-up step. Understanding TLS is the single most important safety concept for any clinician initiating venetoclax therapy.

    Venetoclax’s Complete FDA-Approved Indication Landscape

    Over nearly a decade, venetoclax has accumulated multiple approved indications, alone and in combination, making its approved use landscape one of the most complex of any hematologic oncology drug currently available. As of May 2026, the approved indications are:

    CLL and SLL indications

    Indication 1: CLL or SLL monotherapy Originally approved April 2016 for adult patients with CLL or SLL with 17p deletion who had received at least one prior therapy. Expanded in 2018 to all adult patients with CLL or SLL who had received at least one prior therapy, regardless of 17p deletion status.

    Indication 2: CLL/SLL with obinutuzumab (first-line) Venetoclax plus obinutuzumab (Gazyva) for previously untreated adults with CLL or SLL, approved May 2019. Based on the CLL14 trial showing superior PFS with the combination versus chlorambucil plus obinutuzumab (HR 0.31; p less than 0.0001).

    Indication 3: CLL/SLL with rituximab (relapsed or refractory) Venetoclax plus rituximab for adults with CLL or SLL who have received at least one prior therapy, approved June 2018. Based on the MURANO trial.

    Indication 4: CLL/SLL with acalabrutinib (first-line) — February 2026 Venetoclax plus acalabrutinib (Calquence) for previously untreated adult patients with CLL without 17p deletion or TP53 mutation, approved February 20, 2026. The first all-oral, fixed-duration combination regimen for first-line CLL. Based on the Phase 3 AMPLIFY trial showing 3-year PFS of 76.5% with the doublet versus 66.5% with chemoimmunotherapy (HR 0.65; p=0.004). Treatment duration is fixed at 14 cycles, offering the potential for time off treatment.

    AML indications

    Indication 5: AML combination therapy (older or comorbid adults) Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed AML in adults aged 75 or older or with comorbidities precluding intensive induction chemotherapy, initially approved November 2018 under accelerated approval and confirmed with full approval based on the VIALE-A trial (azacitidine combination, OS 14.7 months versus 9.6 months with placebo; HR 0.66; p less than 0.001).

    Indication 6: AML with Inqovi (decitabine/cedazuridine) — May 2026 As covered in our recent post on the Inqovi plus venetoclax approval, this May 13, 2026 approval created the first all-oral HMA/BCL-2 combination, providing an alternative to the intravenous azacitidine plus venetoclax regimen.

    Other indications (off-label uses with evidence)

    Beyond its FDA-approved indications, venetoclax has substantial evidence and is widely used in clinical practice for:

    • Relapsed or refractory multiple myeloma in patients with t(11;14) translocation
    • Mantle cell lymphoma in combination with BTK inhibitors
    • Various MDS regimens as covered in our Inqovi post

    The CLL Disease Landscape: Who Uses Venetoclax and Why

    Chronic lymphocytic leukemia is the most common leukemia in adults in Western countries, affecting approximately 200,000 Americans and resulting in 18,000 new diagnoses each year in the United States. It is a cancer of mature B lymphocytes that accumulates in the blood, bone marrow, and lymph nodes. Unlike many cancers, CLL often has an indolent course, with many patients living years without requiring treatment, but once treatment is needed, the disease is incurable without allogeneic stem cell transplantation.

    For years, the standard for fit CLL patients was chemoimmunotherapy (FCR, fludarabine-cyclophosphamide-rituximab), and for unfit patients, chlorambucil-based combinations. The BCL-2 inhibitor and BTK inhibitor eras, beginning with ibrutinib in 2013 and venetoclax in 2016, fundamentally transformed the landscape. These targeted oral therapies achieved response rates and progression-free survival outcomes that surpassed decades of chemotherapy development, without the myelosuppression and infectious complications of chemotherapy regimens.

    The February 2026 AMPLIFY-based approval of venetoclax plus acalabrutinib represents the current apex of this evolution: an all-oral, time-limited regimen that eliminates the need for intravenous infusions and offers fixed-duration treatment followed by a treatment-free interval, the first time that has been achievable in the first-line CLL setting without any IV component.

    The AML Disease Landscape: The Population That Needed Venetoclax Most Urgently

    The story of venetoclax in AML is inseparable from the demographics of the disease. Acute myeloid leukemia has a median diagnosis age of approximately 68 years, and for older adults with significant comorbidities, the only prior option was supportive care or low-intensity chemotherapy with response rates below 20% and median survival under 6 months.

    The standard curative-intent treatment for AML, the “7+3” induction regimen of cytarabine and anthracycline, requires weeks of inpatient hospitalization and produces early mortality rates of 10 to 15% in older patients. For a 78-year-old with heart failure, the treatment could kill before the leukemia did.

    The VIALE-A trial (venetoclax plus azacitidine versus azacitidine alone in elderly or comorbid AML) showed median overall survival of 14.7 months in the combination arm versus 9.6 months in the azacitidine-alone arm, with a composite complete remission rate of 66.4% versus 28.3%. For a population with no prior options offering anything close to these numbers, venetoclax-based therapy was transformative.

    Safety: What Every Patient and Clinician Must Know

    Boxed warning: Tumor lysis syndrome

    The most serious risk with venetoclax is TLS, described in detail in the callout box above. Every patient initiating venetoclax must be assessed for TLS risk before starting, and the ramp-up dosing schedule must be followed precisely. Clinicians unfamiliar with venetoclax initiation should review the full prescribing information carefully before the first prescription.

    TLS prophylaxis requirements:

    • Hydration: begin 1 to 2 days before each ramp-up dose; continue at least 24 hours after each ramp-up dose
    • Anti-hyperuricemic agent: allopurinol should be initiated 2 to 3 days before the first dose
    • Electrolyte and renal function monitoring: before each ramp-up dose and at specific intervals after

    Additional boxed warning: serious infections

    Venetoclax can cause severe and fatal infections. Neutropenia is common, particularly with combination regimens. Grade 3 or 4 neutropenia occurs in approximately 50 to 60% of patients on venetoclax-based combinations. Monitor complete blood counts before each cycle and as clinically indicated.

    Common serious adverse reactions

    Neutropenia: Most common grade 3 or 4 toxicity. Granulocyte colony-stimulating factor (G-CSF) may be required. Dose interruption or reduction per prescribing information guidance.

    Thrombocytopenia: Platelet count monitoring required before each cycle.

    Anemia: Common across all indications and combination regimens.

    Serious infections: Pneumonia, sepsis, and other serious infections have been reported. Monitor closely for febrile episodes.

    Nausea and diarrhea: Most common non-hematologic adverse events; typically manageable with dose modification and supportive care.

    Pregnancy

    Venetoclax can cause fetal harm based on its mechanism of action. Females of reproductive potential should use effective contraception during treatment and for at least 30 days after the last dose.

    The Generic Approval: What the Hatch-Waxman Pathway Means

    The Dr. Reddy’s generic approval came through the Abbreviated New Drug Application (ANDA) pathway, the regulatory mechanism created by the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act). Under this pathway, a generic applicant must demonstrate that its product is bioequivalent to the brand-name drug, meaning it produces the same drug concentration in the bloodstream over time, without repeating the extensive safety and efficacy clinical trials that established the drug’s value.

    Dr. Reddy’s filed ANDA 214733 and challenged Venclexta’s patents with a Paragraph IV certification, asserting that the patents were invalid or not infringed. AbbVie and Genentech sued in the U.S. District Court for the District of Delaware in 2020 to block the generic, triggering the standard 30-month litigation stay. The litigation resolved, the last Venclexta regulatory exclusivity expired in 2026, and the FDA approved the generic on May 15, 2026.

    This is the standard pathway through which generic competition enters the U.S. drug market for virtually every major small-molecule medication after patent and exclusivity expiration.

    What generic entry means for pricing: expectations and reality The pattern of price competition following first-generic entry for high-cost oncology drugs is well-established but often slower and less complete than patients hope for. For a drug like Venclexta with a monthly list price historically exceeding $10,000, the first-generic price typically enters at 15 to 30% below the brand list price. Meaningful price competition, 50% or more below brand list price, typically requires multiple generic manufacturers entering the market. For any given patient, the actual out-of-pocket cost depends not on the list price but on their specific insurance coverage, their pharmacy benefit manager’s formulary decisions, whether the generic or brand-name is preferred on their plan, and what assistance programs are available. AbbVie’s existing patient assistance programs for Venclexta and the generic manufacturer’s own pricing strategies will both affect real-world access. Patients currently on Venclexta with inadequate coverage should discuss the generic option with their oncologist and pharmacist as the first step to understanding whether switching to the generic reduces their out-of-pocket costs.

    What This Means for Patients Currently on Venclexta or Starting Venetoclax

    For patients currently on Venclexta

    In most states, a pharmacist can substitute a generic for a brand-name drug at the counter without calling the prescriber, as long as the generic has been rated therapeutically equivalent (AB-rated) by the FDA. If Dr. Reddy’s venetoclax receives an AB rating, your pharmacist may substitute it automatically when you fill or refill your prescription. The clinical effect will be identical: the same molecule, same doses, same therapeutic outcomes.

    If you have concerns about the substitution, you or your prescriber can request “dispense as written” (DAW) on your prescription. However, for generic small-molecule drugs with established bioequivalence, there is no clinical reason to prefer the brand-name over the generic from a therapeutic perspective.

    One practical note: Venetoclax has a complex titration schedule, particularly at initiation. If you have recently completed ramp-up and are at a stable maintenance dose, switching to the generic is straightforward. If you are mid-ramp-up, discuss the timing of any formulation switch with your oncologist to avoid any disruption to your dosing schedule.

    For patients being newly prescribed venetoclax

    Your pharmacist will likely dispense the generic by default, as it will typically be the lower-cost formulary-preferred option. You will receive the same drug at the same doses. The ramp-up schedule, TLS monitoring requirements, and safety monitoring parameters are identical for generic and brand-name venetoclax.

    For related HED coverage of recent venetoclax approvals and the expanding landscape of venetoclax-based regimens, see our post on the Inqovi plus venetoclax approval creating the first all-oral AML regimen and our venetoclax coverage index for a full archive of related posts.

    Sources

    FDA generic approval: Venetoclax tablets 10 mg, 50 mg, 100 mg. ANDA 214733. Dr. Reddy’s Laboratories. Approved May 15, 2026. FDA.gov.

    Drugs.com venetoclax drug information: Venetoclax: Uses, Dosage, Side Effects and Warnings. drugs.com.

    AbbVie/Genentech Venclexta prescribing information: Venclexta (venetoclax) Prescribing Information. AbbVie Inc. and Genentech. Updated 2026.

    Venetoclax plus acalabrutinib AMPLIFY trial approval: FDA Approves Combination Treatment of Venclexta and Acalabrutinib for Previously Untreated CLL. AbbVie/Genentech press release. February 20, 2026.

    AMPLIFY trial (acalabrutinib-venetoclax): Pharmacy Times AMPLIFY coverage. pharmacytimes.com. February 2026.

    VIALE-A trial (venetoclax + azacitidine AML): DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. NEJM. 2020;383(7):617-629.

    MURANO trial (venetoclax + rituximab CLL): Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. NEJM. 2018;378(12):1107-1120.

    CLL14 trial (venetoclax + obinutuzumab): Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. NEJM. 2019;380(23):2225-2236.

    FDA original venetoclax approval (2016): FDA approves venetoclax for CLL with 17p deletion. FDA.gov. April 2016.

    BCL-2 inhibitor mechanism review: BCL-2 Inhibitors in Hematologic Malignancies. PMC8626879.

    Apoptosis: Apoptosis. StatPearls. NCBI.

    CLL overview: Chronic Lymphocytic Leukemia. American Cancer Society.

    AML overview: Acute Myeloid Leukemia. American Cancer Society.

    Hatch-Waxman Act and ANDA pathway: Abbreviated New Drug Application. FDA.gov.

    Patent challenge history: Venclexta patent and exclusivity data. DrugPatentWatch.

    Patient resources: Leukemia and Lymphoma Society: CLL | Leukemia and Lymphoma Society: AML | AbbVie Venclexta patient support | NCI CLL information | NCI AML information

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Venetoclax (generic or brand) carries a boxed warning for tumor lysis syndrome and requires specific ramp-up dosing with mandatory TLS risk assessment and monitoring. Initiation must be supervised by a qualified hematologist or oncologist. Patients currently on Venclexta should not make any changes to their regimen without guidance from their treating oncologist.
  • Up to 76% of People With Alzheimer’s Disease Experience Agitation. The First Non-Antipsychotic Drug Approved for It Just Arrived.

    Up to 76% of People With Alzheimer’s Disease Experience Agitation. The First Non-Antipsychotic Drug Approved for It Just Arrived.

    The essentials: On April 30, 2026, the FDA approved Auvelity (dextromethorphan HBr and bupropion HCl, Axsome Therapeutics) for the treatment of agitation associated with dementia due to Alzheimer’s disease in adults. This is the first FDA-approved treatment for Alzheimer’s disease agitation that is not an antipsychotic, and only the second FDA-approved drug for this indication overall. Auvelity’s first approved indication was major depressive disorder in adults (August 2022). The mechanism: dextromethorphan is an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist; bupropion serves as a CYP2D6 inhibitor that slows dextromethorphan metabolism, substantially increasing dextromethorphan blood levels. Auvelity is a first-in-class treatment combining NMDA antagonism and sigma-1 modulation for agitation in Alzheimer’s disease. Regulatory designation: Breakthrough Therapy Designation (2020). The clinical basis: Phase 3 ADVANCE-1 trial (NCT03226522, 5-week parallel-group RCT, n=308) and Phase 3 ACCORD-2 randomized withdrawal trial (NCT04947553, 26-week randomized withdrawal among responders). ADVANCE-1 primary endpoint: statistically significant reduction in Cohen-Mansfield Agitation Inventory (CMAI) total score at week 5 versus placebo. ACCORD-2 primary endpoint: significantly longer time to relapse (HR 0.276; p=0.001) and lower relapse incidence (8.4% vs. 28.6%) in those continuing Auvelity versus switched to placebo. Important nuance: ADVANCE-2, a second 5-week parallel-group trial (n=408), missed its CMAI primary endpoint, though secondary measures showed numerical improvements. Boxed warning: increased risk of suicidal thoughts and behaviors (antidepressant class warning). Serious risks in elderly patients: seizures, elevated blood pressure, mania. Dosing: one tablet (45 mg dextromethorphan / 105 mg bupropion) twice daily.

    Agitation in Alzheimer’s disease is one of the most distressing and difficult-to-manage aspects of the condition, for patients and for caregivers alike. It is not simply behavioral inconvenience. It encompasses excessive motor activity, verbal aggression, physical aggression, emotional distress, disinhibition, and disruptive irritability. It occurs in an estimated 40 to 76% of people with Alzheimer’s disease over the course of their illness. It is among the leading drivers of nursing home placement. It contributes to caregiver burnout. And until April 30, 2026, the only FDA-approved drug for it was brexpiprazole (Rexulti), an atypical antipsychotic that carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis.

    That warning, applied class-wide to all antipsychotics in this population, has made prescribers appropriately cautious. Antipsychotics are associated with increased risk of death in elderly dementia patients, an association serious enough to generate the FDA’s black box in 2005 for typical antipsychotics and 2008 for atypical antipsychotics. They have nonetheless been widely used off-label for Alzheimer’s agitation because the need was so severe and the alternatives so limited.

    On April 30, 2026, the FDA approved the first non-antipsychotic option. Auvelity (dextromethorphan-bupropion) targets NMDA receptors and sigma-1 receptors through a mechanism entirely distinct from dopamine receptor blockade, providing a pharmacological approach that does not carry the mortality warning applied to antipsychotics in this population.

    The clinical data behind the approval requires honest presentation: it is more nuanced than the headline suggests, and families and clinicians deserve a complete picture.

    What Alzheimer’s Disease Agitation Is and Why It Is So Hard to Treat

    Defining agitation in the context of dementia

    Agitation in Alzheimer’s disease is formally defined as behavior that includes at least one of three domains: excessive motor activity (pacing, handwringing, rocking); verbal aggression (screaming, cursing, threatening); or physical aggression (hitting, biting, scratching). To meet a clinical threshold for treatment, these behaviors must be associated with distress in the patient, represent a change from premorbid behavior, and not be solely attributable to another medical cause or psychosis.

    The Cohen-Mansfield Agitation Inventory (CMAI), the instrument used as the primary efficacy measure in ADVANCE-1, is a validated 29-item scale assessing the frequency of specific agitated behaviors on a scale from 1 (never) to 7 (several times per hour). Higher scores indicate more frequent agitation. The CMAI is the most widely used and well-validated agitation measure in Alzheimer’s disease research and has been accepted by the FDA as a primary endpoint in this indication.

    The pathophysiology behind agitation in Alzheimer’s disease

    Agitation in Alzheimer’s disease is not simply a behavioral response to cognitive decline. It reflects specific neurobiological changes in the Alzheimer’s brain: degeneration of the prefrontal cortex and its connections impairs impulse control and emotional regulation; locus coeruleus neurodegeneration disrupts norepinephrine signaling affecting arousal and stress responses; and aberrant glutamate signaling through NMDA receptors contributes to the excitotoxic and dysregulated neuronal activity associated with agitation and other behavioral symptoms.

    This neurobiological basis for agitation is what makes the NMDA antagonist mechanism of dextromethorphan a rational pharmacological target, distinct from the dopamine-based mechanism of antipsychotics.

    Why off-label antipsychotics have remained standard despite the mortality risk The FDA issued boxed warnings for both typical and atypical antipsychotics in dementia patients between 2005 and 2008, following multiple trials and pharmacovigilance analyses showing a 1.6 to 1.7-fold increased risk of death versus placebo in elderly patients with dementia-related psychosis and behavioral disturbances. Despite this warning, antipsychotics (particularly quetiapine, risperidone, and haloperidol) have continued to be widely prescribed for Alzheimer’s agitation off-label, because the severity of unmanaged agitation creates a real and urgent clinical need that outweighs the mortality risk for many patients in institutional settings. The lack of an approved non-antipsychotic alternative for more than 15 years is the direct reason for this uncomfortable clinical reality. The approval of brexpiprazole in 2023 addressed the first part of the gap: an FDA-approved indication for Alzheimer agitation. But it is still an antipsychotic carrying the same mortality warning. Auvelity addresses the second part: a genuinely mechanistically distinct option without that class-level mortality warning.

    How Auvelity Works in Alzheimer’s Disease Agitation

    Auvelity’s pharmacology in Alzheimer’s disease agitation reflects the same mechanism that supported its 2022 approval for major depressive disorder, applied to a different behavioral target.

    Dextromethorphan: the pharmacologically active agent

    Dextromethorphan (DXM) is a synthetic morphinan compound familiar as the cough-suppressing active ingredient in many over-the-counter cold preparations. At the doses used in Auvelity, which are substantially higher than OTC cough suppressant doses, it acts as an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist.

    NMDA receptor antagonism: NMDA receptors are glutamate receptors involved in synaptic plasticity, learning, and memory but also in excitotoxic signaling when overactivated. In Alzheimer’s disease, aberrant NMDA receptor activity is implicated in both neurodegeneration and behavioral dysregulation. Blocking these receptors, as memantine (Namenda) does (memantine is an FDA-approved NMDA antagonist for moderate to severe Alzheimer’s cognitive symptoms), may reduce the neurochemical substrate for agitation. DXM’s NMDA antagonism is uncompetitive, meaning it binds the receptor channel in its open state, providing a rapid blocking effect that differs pharmacodynamically from memantine’s competitive inhibition.

    Sigma-1 receptor agonism: The sigma-1 receptor is a chaperone protein in the endoplasmic reticulum of neurons involved in neuroplasticity, neuroprotection, and neurotransmitter regulation. Sigma-1 agonism may have independent anxiolytic and neuroprotective effects relevant to Alzheimer’s disease behavioral symptoms.

    Bupropion: the pharmacokinetic enabler

    Bupropion is an aminoketone antidepressant that inhibits CYP2D6, the hepatic enzyme responsible for metabolizing dextromethorphan. When taken alone, DXM is rapidly metabolized by CYP2D6 and does not achieve sustained therapeutic blood levels for neuropsychiatric indications. Bupropion’s CYP2D6 inhibition blocks this metabolism, dramatically increasing DXM blood levels and duration of action, achieving therapeutic NMDA and sigma-1 receptor engagement that OTC doses of DXM cannot.

    This pharmacokinetic partnership is the core mechanism behind Auvelity’s design: bupropion is not chosen for its antidepressant properties in this combination (the bupropion-alone arm in ADVANCE-1 was terminated for futility, confirming bupropion alone has no meaningful effect on Alzheimer’s agitation) but because it makes DXM pharmacologically effective at lower doses with better tolerability.

    The Clinical Evidence: Two Trials, a Complete Picture

    The FDA’s approval is based on two Phase 3 trials: ADVANCE-1 (positive) and ACCORD-2 (positive). A third trial, ADVANCE-2, also informed the totality of evidence but missed its primary endpoint and deserves honest presentation.

    ADVANCE-1 (NCT03226522): the 5-week parallel-group primary efficacy trial

    ADVANCE-1 was a randomized, double-blind, 5-week, parallel-group, placebo-controlled Phase 3 trial in adults with Alzheimer’s disease and moderate to severe agitation. The trial enrolled 308 patients across three arms: Auvelity (n=152), placebo (n=156), and bupropion alone (n, terminated early for futility).

    Primary endpoint: Change in CMAI total score from baseline at week 5.

    Auvelity versus placebo (CMAI change): Auvelity was statistically significantly superior to placebo in reducing CMAI total score at week 5. The improvement was consistent with clinically meaningful agitation reduction.

    Key secondary endpoint: A statistically significantly greater proportion of Auvelity-treated patients were rated by clinicians as “minimally improved” or better on the modified Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (mADCS-CGIC) at week 5.

    Bupropion-alone arm: Terminated for futility at a planned interim analysis, confirming that bupropion alone has no clinically meaningful effect on Alzheimer’s agitation. This is an important finding: it confirms that the efficacy of Auvelity is attributable to the pharmacological effect of enhanced DXM rather than to bupropion’s antidepressant or dopaminergic properties.

    ACCORD-2 (NCT04947553): the 26-week randomized withdrawal durability trial

    ACCORD-2 used a different trial design: an open-label lead-in phase in which all patients received Auvelity, followed by randomization (only among responders who achieved sustained response) to continue Auvelity or switch to placebo for up to 26 weeks. This enriched randomized withdrawal design is appropriate for evaluating whether response is maintained over longer treatment periods.

    Open-label lead-in findings: Patients showed rapid CMAI improvement during the lead-in phase, with a mean reduction of 20.4 points at week 6 (46% reduction from baseline). Approximately 69% achieved at least a 30% response, qualifying them for the randomized withdrawal phase.

    Randomized withdrawal phase primary endpoint: Time to relapse of agitation symptoms.

    OutcomeContinue AuvelitySwitch to placebo
    Hazard ratio for relapse0.276Reference
    p-value0.001—
    Relapse incidence8.4%28.6%

    Patients continuing Auvelity experienced significantly longer time to relapse and substantially lower relapse incidence than those switched to placebo. The approximately 72% reduction in relative relapse risk over 26 weeks confirms durable maintenance of the anti-agitation response.

    The important design caveat: Because ACCORD-2 enrolled only patients who had responded to Auvelity before randomization, its relapse findings should be interpreted in the context of an enriched responder population. It confirms that Auvelity works in those who respond; it cannot speak to what proportion of all Alzheimer’s agitation patients will respond.

    ADVANCE-2: the missed primary endpoint, presented honestly

    ADVANCE-2 was a second 5-week parallel-group trial in 408 participants with Alzheimer’s agitation. Unlike ADVANCE-1, it missed its primary endpoint: the between-group difference in CMAI change at week 5 was −13.8 in the Auvelity arm versus −12.6 in the placebo arm, not reaching statistical significance. Secondary measures showed numerical improvements but these were not formally significant given the failed primary endpoint.

    The FDA’s approval despite ADVANCE-2’s failure reflects the totality of evidence approach: ADVANCE-1 met its primary endpoint, ACCORD-2 met its primary endpoint with a compelling relapse reduction effect, the bupropion-futility finding provides mechanistic clarity, and the long-term safety data is favorable. The difference between ADVANCE-1 and ADVANCE-2 results in the same endpoint is not fully explained and represents genuine clinical uncertainty about the magnitude of benefit in all patients.

    This is important information for families and clinicians: Auvelity works meaningfully for many patients, but the clinical evidence includes one failed parallel-group trial, and not every patient should be expected to respond.

    Auvelity’s Second Indication: How This Differs From the MDD Approval

    Auvelity was first approved in August 2022 for major depressive disorder in adults, based on the GEMINI and ASCEND trials demonstrating rapid antidepressant effects. The Alzheimer’s agitation indication uses the same drug at the same dose but for a neurobiologically and clinically distinct target.

    This creates some complexity for prescribers:

    • The boxed warning for suicidal thoughts in adolescents and young adults is a class effect from the antidepressant pharmacology of bupropion; while the approved Alzheimer’s agitation indication covers elderly adults (who are at lower background risk of this complication), the warning is still on the label
    • In Alzheimer’s disease patients specifically, separating depression from agitation is clinically important: depression is very common in Alzheimer’s disease, and Auvelity’s dual indication means it may be considered for patients who have both conditions, though the trials studied these separately
    • Drug interactions relevant to bupropion’s CYP2D6 inhibition are the same across indications

    Auvelity’s Place in Alzheimer’s Disease Agitation Treatment

    With this approval, two drugs now have FDA approval for Alzheimer’s disease agitation:

    DrugCompanyMechanismApproval dateBoxed warning
    Brexpiprazole (Rexulti)Otsuka/LundbeckAtypical antipsychotic (partial D2 agonist)May 2023Increased mortality in elderly patients with dementia-related psychosis
    Auvelity (dextromethorphan-bupropion)Axsome TherapeuticsNMDA antagonist/sigma-1 agonistApril 30, 2026Suicidal thoughts (antidepressant class); no dementia mortality warning

    The absence of a dementia-specific mortality warning on Auvelity does not mean it is risk-free in this population. It means its mechanism (NMDA antagonism rather than dopamine receptor blockade) does not carry the class-level mortality association established for antipsychotics. Individual patient risk-benefit assessment by a qualified clinician familiar with the patient’s full medical picture remains essential.

    For patients who are not appropriate candidates for antipsychotic therapy, including those with Parkinson’s disease or Lewy body dementia where antipsychotics carry heightened risk, Auvelity may be a particularly relevant option.

    Safety: What the Prescribing Information Covers

    Boxed warning

    Increased risk of suicidal thoughts and behaviors: All antidepressants, including bupropion (a component of Auvelity), carry a class-level boxed warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. The Alzheimer’s agitation indication is in elderly adults, where this risk is substantially lower, but the warning is present on the label. Monitor for clinical worsening and emergence of suicidal thoughts in all patients.

    Warnings specific to elderly Alzheimer’s patients

    Seizure risk: Bupropion is associated with dose-dependent seizure risk. This risk is relevant in elderly Alzheimer’s patients who may have underlying cerebrovascular disease, which independently increases seizure risk. The seizure warning in the prescribing information is particularly relevant in patients with prior seizures, CNS tumors, or concurrent medications that lower the seizure threshold.

    Elevated blood pressure and hypertension: Bupropion inhibits norepinephrine reuptake, which can elevate blood pressure. Monitor blood pressure before starting and periodically during treatment. In elderly patients with cardiovascular disease, this is a clinically important consideration.

    Activation of mania or hypomania: Relevant primarily for patients with undiagnosed or undertreated bipolar disorder.

    Common adverse events (occurring in at least 5% and more than twice placebo in ADVANCE-1)

    Dizziness, nausea, headache, diarrhea, somnolence, dry mouth, hyperhidrosis.

    Drug interactions

    Because bupropion is a CYP2D6 inhibitor, Auvelity will increase the plasma concentration of other CYP2D6-metabolized drugs (including many antidepressants, antipsychotics, beta-blockers, and opioids). Review the full prescribing information for the complete interaction table. This is particularly relevant in elderly patients on multiple medications.

    Dosing

    One extended-release tablet (dextromethorphan 45 mg / bupropion 105 mg) taken twice daily, morning and evening. Do not crush, cut, or chew the extended-release tablet. The tablet can be taken with or without food.

    For Patients, Families, and Caregivers

    What Auvelity is and is not

    Auvelity is a treatment for agitation in Alzheimer’s disease. It is not a cognitive enhancer, does not slow disease progression, and is not a substitute for existing Alzheimer’s disease treatments such as donepezil, memantine, or lecanemab. It specifically targets one of the most disabling behavioral symptoms of Alzheimer’s disease.

    What to expect if starting treatment

    If Auvelity is prescribed, the ACCORD-2 open-label data showed that meaningful agitation improvement became apparent within the first several weeks of treatment, with about 69% of patients achieving at least a 30% improvement by week 6. Not all patients will respond. If no meaningful improvement is seen after an adequate trial, this should prompt discussion with the prescribing clinician about alternative management strategies.

    Caregiver considerations

    Alzheimer’s disease agitation is one of the most significant drivers of caregiver distress and burnout. The availability of a non-antipsychotic FDA-approved option may facilitate earlier treatment consideration in patients where clinicians or families have been reluctant to start antipsychotic therapy.

    The Alzheimer’s Association maintains current resources on managing behavioral symptoms in Alzheimer’s disease, including agitation, with clinical guidance for families navigating these decisions. The Family Caregiver Alliance provides practical support resources specifically for dementia caregivers. The National Institute on Aging maintains current information on all FDA-approved Alzheimer’s treatments.

    For related HED coverage on Alzheimer’s disease treatment advances and FDA approvals, see our post on AVLAYAH, the first gene therapy crossing the blood-brain barrier to reach neurons in Hunter syndrome for context on how the BBB problem in neurological disease is being approached across conditions, and our post on Ocrevus expanding to pediatric multiple sclerosis as another example of 2026 approvals expanding the treatment toolkit for neurological conditions.

    Sources

    FDA press announcement: FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia. FDA.gov. April 30, 2026.

    Axsome Therapeutics press release: Axsome Therapeutics Announces FDA Approval of Auvelity (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease. GlobeNewswire. April 30, 2026.

    Drugs.com approval news: Axsome Therapeutics Announces FDA Approval of Auvelity for Agitation Associated with Dementia. drugs.com. April 30, 2026.

    Psychiatric Times detailed clinical summary: FDA Approves Auvelity for Treatment of Agitation in Alzheimer Disease. psychiatrictimes.com. May 2026.

    NeurologyLive detailed coverage: FDA Approves AXS-05 as New Treatment for Alzheimer Disease Agitation. neurologylive.com. May 2026.

    Neurology Advisor: Auvelity Gains Approval for Agitation in Alzheimer Disease. neurologyadvisor.com. April 2026.

    Conexiant clinical summary: FDA Approves Auvelity for Agitation in Alzheimer’s Disease. conexiant.com. April 2026.

    AJMC: FDA Approves Dextromethorphan-Bupropion for Agitation Due to Alzheimer Disease. ajmc.com. May 2026.

    Pharmacy Times: FDA Approves First Non-Antipsychotic Treatment for Agitation Associated with Alzheimer Disease. pharmacytimes.com. 2026.

    Consultant360: FDA Approves Auvelity for Agitation in Alzheimer Disease Dementia. consultant360.com. May 2026.

    ADVANCE-1 trial registration: NCT03226522. ClinicalTrials.gov.

    ACCORD-2 trial registration: NCT04947553. ClinicalTrials.gov.

    Brexpiprazole Alzheimer agitation FDA approval: FDA approves brexpiprazole for agitation associated with Alzheimer’s disease dementia. FDA.gov. May 2023.

    Auvelity prescribing information: Auvelity (dextromethorphan HBr and bupropion HCl) Prescribing Information. Axsome Therapeutics. 2026.

    Alzheimer’s disease agitation overview: Neuropsychiatric Symptoms in Alzheimer’s Disease. PMC8461428.

    CMAI instrument: Cohen-Mansfield Agitation Inventory. PMC5880688.

    NMDA receptor antagonism in AD: NMDA Receptor Antagonists in Alzheimer’s Disease. PMC5542145.

    Sigma-1 receptor: Sigma-1 Receptor in Neurological Disorders. PMC6370317.

    Dextromethorphan pharmacology: Dextromethorphan. StatPearls. NCBI.

    Bupropion: Bupropion. StatPearls. NCBI.

    CYP2D6: CYP2D6. StatPearls. NCBI.

    Memantine FDA approval: FDA approves memantine for moderate to severe Alzheimer’s disease. FDA.gov.

    Agitation StatPearls: Agitation and Delirium in Elderly. StatPearls. NCBI.

    Patient resources: Alzheimer’s Association: Behavioral Symptoms | Family Caregiver Alliance | National Institute on Aging: Alzheimer’s Treatments

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Auvelity carries a boxed warning for suicidal thoughts and behaviors associated with antidepressant medications. Decisions about treatment for Alzheimer’s disease agitation, including whether Auvelity is appropriate for a specific patient, should be made in close consultation with a qualified neurologist, geriatric psychiatrist, or geriatrician familiar with the patient’s complete medical history, current medications, and clinical circumstances.
  • If Someone in Your Household Has COVID-19, There Is Now an FDA-Approved Pill to Help Prevent You From Getting It Too.

    If Someone in Your Household Has COVID-19, There Is Now an FDA-Approved Pill to Help Prevent You From Getting It Too.

    The essentials: On May 29, 2026, the FDA approved Xocova (ensitrelvir, Shionogi) for post-exposure prophylaxis (PEP) of COVID-19 in adults and adolescents aged 12 years and older who have been exposed to an individual with COVID-19. This is the first and only oral therapy approved in the United States to help prevent COVID-19 after exposure. No previously approved treatment or prophylaxis option for post-exposure prevention of COVID-19 has existed in the United States. The clinical basis: Phase 3 SCORPIO-PEP trial (NCT05897541), 2,387 participants aged 12 and older, global randomized double-blind placebo-controlled, published in the New England Journal of Medicine on May 14, 2026. Primary endpoint: 67% reduction in risk of symptomatic COVID-19 through day 10 (2.9% ensitrelvir vs. 9.0% placebo; risk ratio 0.33; 95% CI 0.22 to 0.49; p less than 0.0001). High-risk subgroup: 76% relative risk reduction (2.4% vs. 9.9%; RR 0.24). Safety: adverse event rates nearly identical between groups (15.1% vs. 15.5%); no treatment-related dysgeusia (altered taste), which affected many patients on nirmatrelvir-ritonavir (Paxlovid). Dosing: 375 mg (3 tablets) on day 1, then 125 mg (1 tablet) daily on days 2 to 5, initiated within 72 hours of symptom onset in the exposed household contact. Not approved for treatment of active COVID-19 in the U.S. Important context: the prior PEP trials of nirmatrelvir-ritonavir and molnupiravir did not meet their primary endpoints; SCORPIO-PEP is the first and only Phase 3 oral antiviral PEP trial to do so.

    COVID-19 has been a fact of life since 2020. More than five years later, it remains endemic: the CDC estimated between 3.8 million and 12.4 million new COVID-19 cases in the United States between October 2025 and May 2026, resulting in as many as 240,000 hospitalizations and 42,000 deaths. The vaccines changed the acute mortality picture. The antivirals, primarily nirmatrelvir-ritonavir (Paxlovid), changed the treatment picture for high-risk individuals once infected. What has never existed is a tool for the gap between those two interventions: an oral option that someone can take after being exposed to a household member with COVID-19, before they become infected themselves.

    On May 29, 2026, that gap closed. The FDA approved ensitrelvir (Xocova) as the first oral option to help prevent COVID-19 after exposure, for adults and adolescents aged 12 years and older following contact with an individual with COVID-19. The pivotal SCORPIO-PEP trial, the only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure, was published in the New England Journal of Medicine two weeks before the approval.

    What Post-Exposure Prophylaxis Means and Why It Is a Different Goal Than Treatment

    To understand what Xocova does and does not do, it is worth being precise about the concept of post-exposure prophylaxis (PEP).

    Post-exposure prophylaxis is the use of a drug or intervention after confirmed or probable exposure to a pathogen, with the goal of preventing infection or disease before symptoms develop. The classic example is HIV PEP: a combination of antiretroviral drugs taken for 28 days after a potential HIV exposure, which significantly reduces the risk of infection if started promptly. The same principle applies to rabies post-exposure vaccination and to some bacterial infections.

    COVID-19 PEP is conceptually identical but pharmacologically distinct: in this case, the goal is to prevent SARS-CoV-2 from establishing productive infection in the body of someone who has just been exposed to an infected person, by suppressing viral replication in the earliest window before the viral load grows to symptomatic levels.

    What this means for understanding Xocova:

    Xocova is not a treatment for active COVID-19 infection in the United States. It is not taken once you have symptoms. It is taken when you have been exposed and do not yet have symptoms. The timing window is critical: it must be initiated within 72 hours of symptom onset in the index case (the household member with COVID-19), which in practice means within days of knowing that someone in your home is infected.

    What Ensitrelvir Is: The 3CL Protease Mechanism

    Ensitrelvir is a SARS-CoV-2 main protease (3CL protease, or Mpro) inhibitor. This is the same general class of target as nirmatrelvir (the active component of Paxlovid), but ensitrelvir is a chemically distinct molecule developed independently by Shionogi through a research collaboration with Hokkaido University.

    The SARS-CoV-2 3CL protease is an enzyme that is essential for viral replication. After the virus enters a cell and its RNA is translated into a large polyprotein, the 3CL protease cleaves this polyprotein into the functional viral components needed to assemble new virus particles. Without this cleavage, functional viral replication cannot proceed. By blocking the 3CL protease, ensitrelvir prevents the virus from producing the components it needs to replicate, suppressing the viral load in exposed individuals before it can rise to the level that produces symptoms and transmission.

    How ensitrelvir differs from nirmatrelvir (the active component of Paxlovid) Both ensitrelvir and nirmatrelvir target the 3CL protease, but they are structurally different molecules with different pharmacological profiles. Nirmatrelvir requires co-administration with ritonavir as a pharmacokinetic booster because it is rapidly metabolized by CYP3A4 in the liver; ritonavir inhibits CYP3A4, extending nirmatrelvir’s half-life. This ritonavir requirement creates the significant drug-drug interaction problem that limits Paxlovid use in many patients on common medications. Ensitrelvir does not require a pharmacokinetic booster. It has adequate oral bioavailability and a sufficiently long half-life on its own. This means Xocova does not carry the same extensive drug interaction liability that makes Paxlovid unusable in patients on many common medications (statins, blood thinners, immunosuppressants, anticonvulsants). Ensitrelvir is still a CYP3A4 substrate and inhibitor and has its own drug interaction considerations (discussed in the safety section), but the interaction profile is less extensive than ritonavir-boosted nirmatrelvir.

    The SCORPIO-PEP Trial: Full Results

    Why this trial matters beyond just this approval

    The findings differ from prior postexposure prophylaxis trials of nirmatrelvir-ritonavir and molnupiravir, which did not show statistically significant protection against COVID-19 in household contacts. Understanding why those trials failed contextualizes why SCORPIO-PEP succeeded.

    The nirmatrelvir-ritonavir PEP trial (EPIC-PEP) did not meet its primary endpoint. The molnupiravir PEP trial similarly did not demonstrate statistically significant protection. These failures were attributed in part to late initiation windows (up to 5 days post-exposure rather than 72 hours post-symptom onset), less strict illness definitions, and different patient populations. The SCORPIO-PEP researchers suggested that earlier treatment initiation, within 72 hours following symptom onset in the index patient, along with a stricter illness definition, may have contributed to the observed efficacy.

    Design

    SCORPIO-PEP (NCT05897541) was a global, randomized, double-blind, placebo-controlled Phase 3 trial enrolling participants at sites in the United States, Europe, Asia, and Latin America. The trial enrolled 2,387 participants aged 12 years and older who tested negative for SARS-CoV-2 and had no symptoms at enrollment despite exposure to a household member with symptomatic COVID-19.

    Key eligibility requirements:

    • Age 12 years or older
    • Negative SARS-CoV-2 test at baseline (RT-PCR confirmed at central laboratory)
    • No COVID-19 symptoms at enrollment
    • Household exposure to a member with symptomatic COVID-19
    • Treatment initiated within 72 hours of symptom onset in the index household case

    Primary endpoint definition: Laboratory-confirmed (central PCR) SARS-CoV-2 infection plus at least one of 14 prespecified COVID-19 symptoms lasting at least 48 hours, through day 10.

    Randomization: 1:1 to ensitrelvir or placebo. Participants were randomly assigned to receive ensitrelvir (375 mg on day 1 and 125 mg on days 2 to 5) or placebo, once daily, and began treatment within 72 hours of when the household member with COVID-19 began showing symptoms.

    Primary analysis population: 2,041 participants with laboratory-confirmed negative baseline tests (excluding 346 who tested positive at baseline and were therefore already infected at enrollment).

    Primary endpoint results

    Outcome through Day 10Ensitrelvir (n=1,030)Placebo (n=1,011)Comparison
    Symptomatic COVID-192.9% (30 patients)9.0% (91 patients)—
    Risk ratio0.33Reference95% CI 0.22 to 0.49
    Relative risk reduction67%—p less than 0.0001

    Source: Hayden FG, Ohmagari N, et al. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. New England Journal of Medicine. Published May 14, 2026. doi:10.1056/NEJMoa2506186. SCORPIO-PEP NCT05897541.

    A 67% relative risk reduction means participants in the ensitrelvir arm were approximately three times less likely to develop symptomatic COVID-19 after household exposure. The absolute risk reduction is 6.1 percentage points (9.0% minus 2.9%), implying that approximately 16 to 17 people would need to receive Xocova to prevent one case of symptomatic COVID-19 from a household exposure.

    High-risk subgroup: the most clinically relevant finding

    The prespecified high-risk subgroup showed a 76% relative risk reduction (2.4% vs. 9.9%; RR 0.24), strengthening the rationale for post-exposure prevention beyond vaccination alone. This subgroup included participants with risk factors for severe COVID-19, the population for whom preventing infection carries the most meaningful clinical consequence. Among participants with risk factors for severe illness, COVID-19 developed in 9 of 382 participants assigned to ensitrelvir and 37 of 374 assigned to placebo.

    The higher relative risk reduction in the high-risk subgroup (76% versus 67% overall) suggests that the drug’s preventive benefit is at least as strong in the people who need it most. This is the group that matters most clinically: older adults, immunocompromised individuals, people with cardiovascular disease or diabetes, and others for whom even a mild COVID-19 infection can trigger worsening of underlying conditions or long COVID.

    Secondary and exploratory findings

    In post-hoc analyses, viral loads and symptom scores appeared lower among ensitrelvir recipients who had infection at baseline or developed infection during the study, suggesting antiviral activity even in those who became infected. This is consistent with the drug’s mechanism, as protease inhibition reduces viral replication regardless of the infection stage.

    Safety

    Xocova was generally well tolerated, with similar rates of adverse events across groups (15.1% in the Xocova group and 15.5% in the placebo group). The most common adverse events (regardless of causality) occurring in greater than or equal to 1% of the Xocova group and at a greater frequency compared to placebo were headache, diarrhea, and cough. There were no reports of altered taste (dysgeusia) attributed to Xocova in the trial.

    The absence of dysgeusia is clinically notable. Altered taste is one of the most commonly reported adverse effects of nirmatrelvir-ritonavir (Paxlovid), affecting a significant proportion of patients and sometimes leading to premature discontinuation. The clean tolerability profile of Xocova in the PEP trial, with adverse events statistically indistinguishable from placebo, supports its suitability for use in asymptomatic or presymptomatic individuals who may have no particular reason to tolerate medication side effects.

    Who Xocova Is and Is Not For

    The approved population

    Xocova is approved for adults and adolescents aged 12 years and older who have been exposed to a person in their household with COVID-19. There is no age cutoff at the upper end, meaning the approval covers older adults, who are among those most likely to benefit from prevention.

    The label says “household contact” specifically. The SCORPIO-PEP trial enrolled household contacts, meaning people living in the same home as an infected person. This reflects the highest-risk exposure scenario (prolonged close contact, shared indoor air space), and this is where the evidence was generated.

    Critical timing requirement

    Xocova must be initiated within 72 hours of the symptom onset of the infected household contact. This is not a treatment taken when you start feeling sick; it is a prevention taken when you learn that someone in your home is sick. The logistics of this matter practically: you will need to have a prescription in advance or be able to obtain one quickly, because the 72-hour window can close rapidly.

    Who should discuss Xocova with their prescriber first

    Several groups have specific considerations before using Xocova:

    Drug interactions: Ensitrelvir is a CYP3A4 substrate and inhibitor. While it does not require ritonavir boosting, it can affect the levels of other CYP3A4-metabolized medications and can have its own levels affected by strong CYP3A4 inducers or inhibitors. Review the full prescribing information or consult a pharmacist before initiating in patients on chronic medications.

    Immunocompromised patients: While this group is among those most likely to benefit, they may also have complex drug regimens that require interaction screening before initiating Xocova.

    Pregnancy and breastfeeding: Safety data in pregnancy is limited. The decision to use Xocova during pregnancy should involve a discussion with a clinician familiar with the patient’s overall situation.

    Patients who have already been vaccinated and boosted: The trial enrolled participants with diverse vaccination backgrounds. Whether current vaccination status meaningfully modifies the incremental benefit of Xocova PEP is not yet established by the trial data. For high-risk patients, particularly those who are immunocompromised and may have blunted vaccine responses, Xocova may provide meaningful additional protection on top of vaccination.

    Who Xocova is not for in the U.S.

    Xocova is not approved in the United States for the treatment of active COVID-19 infection. If you have COVID-19 symptoms, Xocova is not the appropriate option; nirmatrelvir-ritonavir (Paxlovid) or remdesivir (Veklury) are the relevant approved treatments for symptomatic disease. Xocova is specifically for prevention in people who have been exposed but are not yet symptomatic.

    Dosing

    DayDoseNumber of tablets
    Day 1 (loading dose)375 mg3 tablets (125 mg each)
    Days 2 to 5125 mg once daily1 tablet per day
    Total treatment duration5 days—
    Timing requirementBegin within 72 hours of symptom onset in the exposed household contact—
    AdministrationOral, with or without food—

    The Regulatory Context: Japan, Global Status, and the Path to the U.S.

    Ensitrelvir’s regulatory history is global and worth understanding:

    Xocova received emergency regulatory approval in Japan in November 2022 and full approval in March 2024 for the treatment of COVID-19 based on results from SCORPIO-SR, a Phase 3 study conducted in Asia during the Omicron-dominant phase of the pandemic. Ensitrelvir is also approved in Japan and Singapore for post-exposure prophylaxis.

    The approval occurred ahead of the Prescription Drug User Fee Act (PDUFA) action date of June 16, 2026, meaning the FDA completed its review approximately 2.5 weeks before the scheduled deadline. The U.S. approval is specifically and only for post-exposure prophylaxis; treatment of active infection is not approved in the United States. Wockhardt has submitted a Marketing Authorization Application to the European Medicines Agency; regulatory reviews are also ongoing in other jurisdictions.

    This is a meaningful distinction: ensitrelvir has been approved and used in Asia for treatment and prevention; the FDA’s U.S. approval is limited to the PEP indication where the Phase 3 evidence base is strongest and the clinical need is most clearly defined.

    What This Means for COVID-19 Prevention Going Forward

    The approval of Xocova represents a genuine expansion of the COVID-19 prevention toolkit. The current landscape before this approval offered vaccines for prophylaxis and antivirals for treatment, but no pharmacological bridge for the household exposure scenario, which is one of the highest-risk settings for transmission.

    The SCORPIO-PEP data suggests several populations that may benefit most:

    Older adults in congregate settings: COVID-19 disproportionately affects older adults with greater risk for severe illness and death in close-community settings, such as long-term care facilities. When a COVID-19 case is identified in a long-term care facility, Xocova PEP for exposed residents aged 12 and older is now a pharmacologically supported prevention strategy.

    Immunocompromised individuals: Those with impaired vaccine responses, including transplant recipients, patients on immunosuppressive therapy, and patients with hematologic malignancies, have limited protection from vaccination alone. PEP with Xocova provides an additional layer of prevention after household exposure.

    Caregivers of high-risk individuals: A caregiver who lives with and provides daily assistance to an older adult with multiple comorbidities has both personal and protective reasons to prevent becoming a COVID-19 vector. If a household member develops COVID-19, PEP for the caregiver reduces the risk of transmission to the high-risk person they serve.

    Long COVID prevention: People diagnosed with COVID-19 had increased rates of both new and worsening neurologic, cardiovascular, respiratory, and renal conditions during the year following infection. Preventing acute infection prevents the downstream risk of these post-COVID complications for individuals who successfully avoid infection with Xocova.

    For related HED coverage of COVID-19 treatment and prevention developments, see our coverage of nirmatrelvir-ritonavir (Paxlovid) and its drug interaction challenges and our post on Foundayo (orforglipron) and the post-marketing safety requirements for newer antivirals and metabolic drugs for context on how the FDA approaches post-marketing surveillance for novel mechanisms in new populations.

    Sources

    FDA approval / Shionogi press release: Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure. businesswire.com. May 31, 2026.

    Drugs.com approval news: FDA Approves Xocova (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure. drugs.com. June 1, 2026.

    SCORPIO-PEP primary NEJM publication: Hayden FG, Ohmagari N, et al. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. New England Journal of Medicine. Published May 14, 2026. doi:10.1056/NEJMoa2506186.

    SCORPIO-PEP trial registration: NCT05897541. ClinicalTrials.gov.

    Shionogi NEJM publication announcement: New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure. shionogi.com. May 14, 2026.

    Contagion Live approval coverage: FDA Approves Ensitrelvir as First Oral Post-Exposure Prevention Option for COVID-19. contagionlive.com. May 2026.

    Patient Care Online: FDA Approves Xocova as First Oral COVID-19 Postexposure Prophylaxis Option. patientcareonline.com. June 2026.

    PharmExec coverage: FDA Approves Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy. pharmexec.com. June 2026.

    Pharmacy Times SCORPIO-PEP results: Ensitrelvir Demonstrates Significant COVID-19 Post-Exposure Prophylaxis Efficacy in Phase 3 Trial. pharmacytimes.com. 2026.

    Conexiant clinical summary: Ensitrelvir Reduced COVID After Household Exposure. conexiant.com. June 2026.

    Cardiology Advisor pre-approval coverage: Ensitrelvir Under Review for COVID-19 Postexposure Prophylaxis. thecardiologyadvisor.com. September 2025.

    Xocova prescribing information: XOCOVA (ensitrelvir) Prescribing Information. Shionogi. 2026.

    Paxlovid FDA approval: FDA approves nirmatrelvir-ritonavir (Paxlovid) for treatment of COVID-19. FDA.gov.

    Ensitrelvir mechanism: Ensitrelvir as a SARS-CoV-2 Protease Inhibitor. PMC9941555.

    3CL protease and SARS-CoV-2 replication: SARS-CoV-2 Main Protease Structure. PMC9941555.

    Post-exposure prophylaxis concept: Post-Exposure Prophylaxis. StatPearls. NCBI.

    HIV PEP reference: HIV Post-Exposure Prophylaxis. CDC.

    CYP3A4 drug interactions: CYP3A4. StatPearls. NCBI.

    Patient resources: CDC COVID-19 information | Xocova patient information | CDC COVID-19 treatments and prevention

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Xocova is a prescription medication approved only for post-exposure prophylaxis (PEP) of COVID-19 and is not approved for the treatment of active COVID-19 infection in the United States. Patients with COVID-19 symptoms should contact their healthcare provider. The 72-hour initiation window after symptom onset in the exposed household contact is a firm requirement.
  • Resistant Gram-Negative UTIs Just Got a New Weapon. Here Is What Zaynich Is and What the ENHANCE-1 Trial Data Shows.

    Resistant Gram-Negative UTIs Just Got a New Weapon. Here Is What Zaynich Is and What the ENHANCE-1 Trial Data Shows.

    📌 The essentials On May 29, 2026, the FDA approved Zaynich (cefepime and zidebactam, Wockhardt) for the treatment of adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. What makes it mechanistically distinctive: zidebactam is a non-beta-lactam beta-lactamase inhibitor that acts as a beta-lactam enhancer, functioning both as a beta-lactamase inhibitor and as an independent antibacterial agent targeting PBP2. This dual role allows the combination to overcome multiple resistance mechanisms including carbapenem-hydrolyzing metallo-beta-lactamases (MBLs), which no currently approved beta-lactam/beta-lactamase inhibitor combination can address. Approved organisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa. The clinical basis: Phase 3 ENHANCE-1 trial (NCT04979806), 530 patients, double-blind, randomized 2:1 Zaynich versus meropenem. Primary endpoint: composite clinical cure and microbiologic response rate 89.0% with Zaynich versus 68.4% with meropenem (difference +20.6%; 95% CI 12.3 to 29.5). Non-inferiority and superiority both achieved. Dosing: 3 g (cefepime 2 g plus zidebactam 1 g) intravenous infusion every 8 hours for 7 to 10 days, infused over 1 hour. Dose adjustment required for renal impairment. Regulatory designations: Qualified Infectious Disease Product (QIDP), Fast Track. Global status: also approved in India May 27, 2026; EMA Marketing Authorization Application submitted.

    Complicated urinary tract infections are not the same as the straightforward UTIs that can be treated with a few days of oral antibiotics. They involve the upper urinary tract (pyelonephritis, kidney infection), occur in patients with structural or functional urinary tract abnormalities, affect hospitalized patients or those with indwelling urinary catheters, or are caused by pathogens that resist the antibiotics typically used for uncomplicated infections. In the United States, cUTIs account for more than 600,000 hospitalizations annually, and the proportion caused by multidrug-resistant (MDR) Gram-negative bacteria is growing.

    The antimicrobial resistance crisis in Gram-negative bacteria is not a future problem. It is a present clinical reality. Carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa are among the pathogens designated by the CDC as urgent threats. Carbapenems, the last-resort antibiotics for many Gram-negative infections, are failing against an expanding proportion of resistant organisms. New antibiotics that can overcome carbapenem resistance mechanisms, particularly metallo-beta-lactamases, are a clinical priority.

    On May 29, 2026, the FDA approved Zaynich (cefepime and zidebactam), the first approved antibiotic combination in which the beta-lactamase inhibitor component also functions as an independent antibacterial agent. The ENHANCE-1 trial showed not only non-inferiority to meropenem (a carbapenem and the current gold standard for complicated Gram-negative infections) but superiority: a 20.6 percentage point higher composite cure rate. For an antibiotic trial, that is a striking result.

    The Antimicrobial Resistance Context: Why New Gram-Negative Antibiotics Matter

    Antimicrobial resistance in Gram-negative bacteria operates through several distinct mechanisms that have made treatment of serious infections increasingly challenging.

    Beta-lactamase enzymes: the central resistance mechanism

    Beta-lactamases are enzymes produced by bacteria that break down the beta-lactam ring, the core structure of penicillins, cephalosporins, and carbapenems. By hydrolyzing the beta-lactam ring, these enzymes inactivate the antibiotic before it can reach its target (penicillin-binding proteins, or PBPs) on the bacterial cell wall.

    The major beta-lactamase classes relevant to Gram-negative resistance include:

    • Extended-spectrum beta-lactamases (ESBLs): Inactivate most penicillins and cephalosporins. Very common in E. coli and Klebsiella. Previously manageable with carbapenems.
    • KPC-type carbapenemases (Klebsiella pneumoniae carbapenemase): Inactivate carbapenems. Now widespread in Klebsiella, Enterobacter, and other Enterobacterales.
    • Metallo-beta-lactamases (MBLs) including NDM, VIM, and IMP: Also inactivate carbapenems. Critically, unlike serine-based carbapenemases, MBLs use a zinc-dependent mechanism that conventional serine-beta-lactamase inhibitors (clavulanate, tazobactam, avibactam) cannot block.

    The MBL gap is the most clinically urgent. Approved combinations such as ceftazidime-avibactam (Avycaz) and meropenem-vaborbactam (Vabomere) are effective against KPC-producing organisms but cannot inhibit MBL-producing bacteria. For patients with MBL-producing infections, treatment options have been extremely limited.

    Why Pseudomonas aeruginosa is a separate challenge

    Pseudomonas aeruginosa is an intrinsically resistant Gram-negative bacterium that combines multiple resistance mechanisms: it produces beta-lactamases, it can upregulate efflux pumps that expel antibiotics from the cell, and it can downregulate outer membrane porins that antibiotics use to enter. Many standard cephalosporins have limited activity against Pseudomonas; cefepime has historically been among the more active cephalosporins against this pathogen, making it a rational backbone for the Zaynich combination.

    Why zidebactam is different from all previously approved beta-lactamase inhibitors All previously approved beta-lactamase inhibitors (clavulanate, sulbactam, tazobactam, avibactam, vaborbactam, relebactam) work by inhibiting beta-lactamase enzymes, preventing them from destroying the antibiotic partner. Zidebactam does this too, but it also independently targets PBP2 in Gram-negative bacteria, the same penicillin-binding protein targeted by carbapenems. By directly occupying PBP2, zidebactam restores susceptibility to cefepime in bacteria that have become resistant through beta-lactamase production, because even if some residual beta-lactamase activity breaks down cefepime molecules, zidebactam’s independent PBP2 targeting contributes directly to bacterial cell wall disruption. This beta-lactam enhancer mechanism is what makes Zaynich active against MBL-producing organisms where avibactam-containing combinations fail. Avibactam cannot inhibit MBLs; zidebactam bypasses the need to inhibit them.

    How Zaynich Works: The Dual Mechanism in Detail

    Zaynich combines two drugs that act synergistically through distinct but complementary mechanisms targeting the Gram-negative bacterial cell wall:

    Cefepime: the fourth-generation cephalosporin

    Cefepime is a fourth-generation cephalosporin with good activity against both Gram-negative and some Gram-positive organisms. In Enterobacterales, cefepime primarily targets PBP3 and PBP1a/1b. In Pseudomonas aeruginosa, it targets PBP3. PBP binding inhibits cell wall synthesis, ultimately causing bacterial lysis. Cefepime’s advantage over earlier cephalosporins is its stability against many (but not all) beta-lactamases and its enhanced ability to penetrate Gram-negative outer membranes.

    Zidebactam: the beta-lactam enhancer

    Zidebactam is a novel synthetic molecule classified as a diazabicyclooctane (DBO), structurally similar to avibactam and relebactam. Its two mechanisms work simultaneously:

    As a beta-lactamase inhibitor: Zidebactam inhibits serine-beta-lactamases including Class A (ESBLs, KPC), Class C (AmpC), and Class D (OXA) beta-lactamases, protecting cefepime from enzymatic degradation. Importantly, it is also active against several serine-carbapenemases, extending coverage to KPC-producing organisms.

    As a direct PBP2 targeting agent: Zidebactam binds PBP2 with high affinity in Gram-negative pathogens. This independent bactericidal action contributes to cell wall disruption independent of its beta-lactamase inhibitory role. For MBL-producing organisms (NDM, VIM, IMP), where the MBL enzyme cannot be inhibited by any current serine-targeting inhibitor, zidebactam’s PBP2 binding provides direct antibacterial activity that partially compensates for ongoing cefepime destruction by the MBL. This is the mechanism that gives the combination activity against MBL producers.

    The combined effect is coverage of PBP1a/1b, PBP2, and PBP3 simultaneously in the majority of clinically relevant Gram-negative pathogens, across diverse resistance mechanisms.

    The ENHANCE-1 Trial: Full Results

    Design

    ENHANCE-1 (NCT04979806) was a Phase 3, randomized, double-blind, multicenter, non-inferiority trial. The trial enrolled 530 hospitalized adults at 64 clinical sites in the United States, Europe, Latin America, China, and India.

    Eligible patients: Adults aged 18 and older with a clinical diagnosis of cUTI or acute pyelonephritis, with or without concurrent bacteremia, requiring intravenous antibiotic therapy.

    Randomization: 2:1 to:

    • Zaynich: cefepime 2 g plus zidebactam 1 g (total 3 g) by 1-hour IV infusion every 8 hours for 7 to 10 days (n=352)
    • Meropenem: 1 g by 30-minute IV infusion every 8 hours for 7 to 10 days (n=177)

    Dose adjustments for renal function were specified per protocol for both arms.

    Primary endpoint: Composite of clinical cure and microbiologic response at the test-of-cure (TOC) visit (approximately 7 to 14 days after end of treatment) in the modified microbiological intent-to-treat (mMITT) population.

    Non-inferiority margin: The trial was powered for non-inferiority but also had a pre-specified superiority analysis.

    Primary endpoint results

    Outcome at test-of-cure visitZaynich (n=352)Meropenem (n=177)Treatment difference
    Composite clinical cure and microbiologic response rate89.0%68.4%+20.6% (95% CI 12.3 to 29.5)
    Non-inferiority achievedYes—Confidence interval lower bound far above zero
    Superiority achievedYes—Lower bound of 95% CI (12.3%) above zero

    Source: ENHANCE-1, NCT04979806. Presented at IDSA 2025 Open Forum. Wockhardt press release. June 1, 2026.

    The 20.6 percentage point superiority over meropenem in composite clinical and microbiologic response deserves specific comment. Meropenem is not a weak comparator. It is among the broadest-spectrum, most reliably active intravenous antibiotics available for Gram-negative cUTI, and it was the appropriate comparator given the spectrum of Gram-negative organisms targeted. An antibiotic demonstrating superiority over meropenem in a well-conducted Phase 3 trial is an unusual and clinically meaningful result.

    The likely explanation lies in the patient population and organism mix: a proportion of patients in the trial carried organisms with resistance mechanisms that meropenem could not fully overcome but that Zaynich’s broader mechanism could address. The trial’s global enrollment across geographies with high burdens of ESBL-producing and carbapenem-resistant organisms supports this interpretation.

    Safety

    Zaynich was generally well tolerated in ENHANCE-1. The most common adverse reactions, occurring in at least 2% of Zaynich-treated patients, were diarrhea, hypertension, headache, and hypokalemia. These are consistent with the known safety profiles of the individual components.

    Cefepime-specific safety considerations:

    • Neurotoxicity: cefepime is associated with neurotoxic effects including encephalopathy, myoclonus, and seizures, particularly at high doses or in patients with renal impairment receiving unadjusted doses. The prescribing information specifically warns that serious neurologic adverse reactions have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime.
    • Hypersensitivity reactions: including anaphylaxis, consistent with the cephalosporin class.
    • Clostridioides difficile-associated diarrhea (CDAD): as with all antibiotics, C. diff colitis is a risk with broad-spectrum agents.

    Approved Organisms and the Susceptibility Testing Requirement

    Zaynich is approved specifically for cUTI caused by the following susceptible organisms, as determined by appropriate microbiologic testing:

    • Escherichia coli
    • Klebsiella pneumoniae
    • Proteus mirabilis
    • Enterobacter cloacae complex
    • Pseudomonas aeruginosa

    The word “susceptible” is clinically operative. Zaynich should be used when the infecting organism has been confirmed or is strongly suspected to be one of these organisms based on culture and susceptibility data. Empirical use without culture data should follow local epidemiology and institutional antibiotic stewardship guidance.

    The approved coverage does not include Gram-positive organisms, anaerobes, or Acinetobacter species. For patients with polymicrobial infections or suspected Gram-positive co-infection, additional agents may be required.

    Dosing and Administration

    ParameterDetails
    Standard dose3 g (cefepime 2 g plus zidebactam 1 g) IV every 8 hours
    Infusion duration1 hour per infusion
    Treatment duration7 to 10 days
    Renal dose adjustmentRequired for eGFR below 50 mL/min per 1.73m²; see full prescribing information
    Geriatric patientsExtra caution; monitor renal function and adjust dose accordingly given cefepime neurotoxicity risk
    PreparationSterile powder reconstituted per prescribing information instructions before IV infusion

    Regulatory Designations and Context

    Zaynich received two FDA designations reflecting the urgency of the antimicrobial resistance problem it addresses:

    Qualified Infectious Disease Product (QIDP): A designation created by the GAIN Act (Generating Antibiotic Incentives Now) specifically to incentivize development of antibiotics against serious or life-threatening infections, including drug-resistant Gram-negative bacteria. QIDP status provides 5 additional years of market exclusivity, priority review, and fast track eligibility.

    Fast Track designation: Provides more frequent FDA interactions during development and eligibility for rolling review.

    Globally, Zaynich was also approved by the Drugs Controller General of India (DCGI) on May 27, 2026, two days before U.S. approval. Wockhardt has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA). The drug was made available through expanded access programs in multiple countries before formal approval.

    Where Zaynich Fits in the Antibiotic Landscape for Resistant Gram-Negative cUTI

    The antibiotic options for MDR Gram-negative cUTI have expanded modestly in recent years, with each agent covering a different subset of resistance mechanisms:

    AgentCovers ESBLsCovers KPCCovers MBLs (NDM/VIM/IMP)Covers P. aeruginosa
    Meropenem (carbapenem)YesNo (KPC destroys it)NoYes
    Ceftazidime-avibactam (Avycaz)YesYesNoYes
    Meropenem-vaborbactam (Vabomere)YesYesNoLimited
    Imipenem-cilastatin-relebactam (Recarbrio)YesYesNoYes
    Ceftolozane-tazobactam (Zerbaxa)Yes (limited)NoNoEnhanced P. aeruginosa coverage
    Zaynich (cefepime-zidebactam)YesYesPartial (via PBP2 mechanism)Yes

    The MBL coverage column is the most important for clinical decision-making. For patients with infections confirmed or strongly suspected to be caused by NDM-producing, VIM-producing, or IMP-producing organisms, Zaynich’s PBP2-targeting mechanism provides an option where no previously approved combination is reliably effective. This is the niche where Zaynich represents the most meaningful advance.

    For general ESBL-producing and KPC-producing infections, the clinical choice between Zaynich, ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam will depend on local susceptibility patterns, institutional formulary decisions, and patient-specific factors.

    Antibiotic Stewardship Considerations

    Zaynich is a broad-spectrum intravenous antibiotic approved for a specific clinical indication. Its role should be guided by antimicrobial stewardship principles:

    • Use based on culture and susceptibility data whenever possible
    • Employ empirically when MDR pathogens are strongly suspected based on prior culture history, recent antibiotic exposure, healthcare-associated acquisition, or local epidemiology
    • De-escalate to narrower-spectrum agents when susceptibility data permit
    • Follow institutional stewardship guidelines and consult infectious disease specialists for complex MDR cases

    For related HED coverage on the regulatory framework that incentivizes antibiotic development and on drug safety monitoring for serious infections, see our post on Hepcludex (bulevirtide) as the first approved treatment for hepatitis delta and our post on Tavneos (avacopan) and the serious liver injury warning in post-market surveillance.

    Sources

    FDA approval / Wockhardt press release: Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam). PRNewswire. June 1, 2026.

    Drugs.com approval news: FDA Approves Zaynich (cefepime and zidebactam) for the Treatment of Complicated Urinary Tract Infections. drugs.com. May 30, 2026.

    Urology Times clinical coverage: FDA approves cefepime and zidebactam for complicated UTI. urologytimes.com. May 2026.

    Renal and Urology News: Zaynich Approved for Complicated Urinary Tract Infections in Adults. renalandurologynews.com. June 2026.

    Contemporary OB/GYN: FDA approves cefepime and zidebactam intravenous antibiotic to treat adults with cUTI. contemporaryobgyn.net. June 2026.

    ENHANCE-1 IDSA 2025 Open Forum presentation: Genov P, Mladenov B, Slaitas D, et al. Efficacy of beta-lactam enhancer based zidebactam-cefepime combination (WCK 5222) versus meropenem in adults with cUTI or acute pyelonephritis: global, randomized, double-blind, Phase 3 trial. Open Forum Infectious Diseases. 2026;ofaf695.1402. doi:10.1093/ofid/ofaf695.1402.

    ENHANCE-1 trial registration: NCT04979806. ClinicalTrials.gov.

    Zaynich full prescribing information: ZAYNICH (cefepime and zidebactam) Prescribing Information. Wockhardt. 2026.

    Beta-lactamases and resistance mechanisms: Beta-Lactamase Inhibitors. PMC7279573.

    Complicated UTI overview: Complicated Urinary Tract Infections. StatPearls. NCBI.

    AMR in Gram-negative bacteria: Gram-Negative Bacterial Infections. StatPearls. NCBI.

    Pseudomonas aeruginosa: Pseudomonas aeruginosa Infections. StatPearls. NCBI.

    Cefepime neurotoxicity: Cefepime-Induced Neurotoxicity. PMC7459434.

    Cefepime mechanism: Cefepime. StatPearls. NCBI.

    Cephalosporin hypersensitivity: Cephalosporin Allergy. StatPearls. NCBI.

    C. diff associated diarrhea: Clostridioides Difficile. StatPearls. NCBI.

    CDC AMR urgent threats: CDC Antibiotic Resistance Threats Report. cdc.gov.

    CDC antibiotic stewardship core elements: Core Elements of Antibiotic Stewardship. cdc.gov.

    QIDP and GAIN Act: GAIN Act Frequently Asked Questions. FDA.gov.

    Fast Track designation: Fast Track. FDA.gov.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Zaynich is an intravenous antibiotic requiring prescription and clinical oversight. Decisions about antibiotic selection for complicated urinary tract infections should be made by a qualified clinician based on culture and susceptibility data, patient-specific factors including renal function, and institutional antimicrobial stewardship guidelines.

  • The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    I have all the data including the nuanced primary endpoint story. This is one of the more interesting approval stories of 2026 because the full ITT analysis technically missed the noninferiority margin but the FDA approved based on the modified ITT. That distinction must be presented honestly and clearly. Here is the full compliant post.

    The First Needle-Free Mealtime Insulin Option for Children Just Got FDA Approval. Here Is What the INHALE-1 Data Shows, Including the Part That Is More Complicated Than the Headlines Suggest.

    By M. Rodriguez, CST/CMA/CCA | Health Evidence Digest

    📌 The essentials On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder, MannKind Corporation) for use in children and adolescents aged 6 years and older with type 1 or type 2 diabetes. This expands Afrezza’s label beyond adults (approved June 2014) to include pediatric patients for the first time. Afrezza is the first and only inhaled mealtime insulin available to pediatric patients in the more than 100-year history of insulin therapy. The clinical basis: Phase 3 INHALE-1 trial (NCT04974528), 230 children and adolescents aged 4 to 17 years, 26-week randomized open-label comparison of Afrezza plus basal insulin versus multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin. Published in Diabetes Care, January 2026. Important nuance on the primary endpoint: the full intent-to-treat (ITT) analysis showed a between-group HbA1c difference of 0.435%, narrowly exceeding the prespecified noninferiority margin of 0.4%. This was attributed to a single non-adherent patient. A pre-specified modified ITT (mITT) analysis excluding this patient showed a difference of 0.370%, meeting noninferiority. The FDA approved based on the totality of evidence including the mITT analysis, long-term safety data, lung function data, and 20-plus years of Technosphere inhaled insulin research. Pulmonary safety: no significant difference in lung function between groups at 26 weeks. FEV1 remained within normal range throughout. No serious pulmonary adverse events. Secondary findings: significantly less weight gain and significantly higher treatment satisfaction in Afrezza-treated patients and parents versus MDI. Age minimum: 6 years and older. Price: eligible patients can access Afrezza for $35 or less per month through MannKind Cares.

    Insulin has been injected for more than 100 years. Every child diagnosed with type 1 diabetes has faced the same reality: multiple daily needle sticks, in school, at meals, at sports practice, at birthday parties, at sleepovers. For most of that century, there was no alternative.

    On May 29, 2026, the FDA approved Afrezza (insulin human inhalation powder) for use in children and adolescents aged 6 and older, making it the first needle-free mealtime insulin option ever available to pediatric patients. The drug that has been available to adult patients with diabetes since 2014 can now be prescribed to the children and adolescents for whom injection anxiety, school logistics, and social friction around insulin administration are documented barriers to adherence and glycemic control.

    The clinical evidence behind the approval requires honest presentation. The pivotal trial technically missed its pre-specified primary endpoint in the full analysis, approved based on a modified analysis and a totality of supporting evidence. That is a fact families and prescribers deserve to understand, not a reason to dismiss a drug that addresses one of the most durable unmet needs in pediatric diabetes care.

    Why Needle Anxiety in Children With Diabetes Is a Clinical Problem, Not a Parental Preference

    Needle anxiety in children with diabetes is one of the most consistently documented barriers to optimal insulin therapy in pediatric endocrinology. It is not simply a matter of children disliking injections; it is a behavioral pattern with measurable downstream consequences for glycemic control.

    Fear of injections drives dose skipping, delayed mealtime insulin administration, avoidance of insulin correction doses when blood glucose runs high, and in some cases refusal to initiate or intensify insulin therapy at diagnosis. In school settings specifically, the logistics of supervised insulin administration, the social visibility of the act, and the fear of peer reactions around needles create practical barriers that affect real-world glycemic management differently from how they appear in clinical trials conducted in controlled settings.

    The consequences of suboptimal mealtime insulin dosing in children compound over time. Chronic hyperglycemia accelerates the development of diabetic retinopathy, nephropathy, and neuropathy. In children who spend years with elevated post-meal glucose excursions because they skip or reduce mealtime insulin doses to avoid injections, the long-term risk burden is real and well-established.

    This is the clinical backdrop against which the Afrezza pediatric approval should be understood. Whether inhaled insulin achieves slightly different HbA1c values than injections in a controlled trial is relevant; whether it enables children who currently under-dose or skip mealtime insulin to take it more consistently is equally relevant, and arguably more important for the majority of real-world pediatric patients.

    What Afrezza Is and How the Technosphere Delivery System Works

    Afrezza is an inhaled formulation of recombinant human insulin that uses MannKind’s proprietary Technosphere drug delivery platform to achieve rapid pulmonary absorption. The drug is provided as a dry powder in a foil blister cartridge and is inhaled through a small, pocket-sized inhaler at the start of each meal.

    The Technosphere platform consists of fumaryl diketopiperazine (FDKP) particles, which are engineered to form microparticles that carry insulin into the deep lung. When these particles reach the alveolar surface, they dissolve rapidly in the aqueous lung lining, releasing insulin that is then absorbed into the pulmonary capillary bloodstream. This pulmonary absorption pathway bypasses the subcutaneous tissue depot that slows absorption with injected insulin.

    The pharmacokinetic result is what makes Afrezza clinically distinctive: it is the fastest-acting insulin available. In adults, Afrezza reaches peak insulin concentration within approximately 12 to 15 minutes of inhalation, compared to 55 to 90 minutes for rapid-acting injectable analogs like aspart, lispro, or glulisine. The duration of action is correspondingly shorter, approximately 3 hours, compared to 3 to 5 hours for injectable rapid-acting analogs.

    Why ultra-rapid onset matters for post-meal glucose control Mealtime insulin is meant to blunt the glucose spike that follows carbohydrate absorption. For injected rapid-acting insulin analogs, there is a well-documented mismatch: the insulin starts working 15 to 30 minutes after injection but glucose starts rising almost immediately upon eating. Patients are instructed to inject 15 to 20 minutes before eating, but adherence to pre-meal injection timing is low in practice, particularly in children and adolescents in real-world settings. Afrezza’s rapid onset means it can be inhaled at the start of the meal rather than before and still reach peak effect while glucose is rising from that meal. This timing advantage is pharmacologically meaningful and practically significant in school-age children who cannot predict meal timing, must eat quickly, or cannot leave class early to administer insulin before lunch.

    The INHALE-1 Trial: What the Data Shows, Including the Nuance

    Design

    INHALE-1 (NCT04974528) was a 26-week, open-label, randomized, multicenter Phase 3 clinical trial with a 26-week safety extension, enrolling children and adolescents aged 4 to 17 years with type 1 or type 2 diabetes. The open-label design was necessary because blinding inhaled versus injected insulin in children is not practically feasible.

    Enrollment (n=230): Randomized 1:1 to:

    • Afrezza inhalation powder plus basal insulin (n approximately 115)
    • Multiple daily injections (MDI) of rapid-acting insulin analog plus basal insulin (n approximately 115)

    Primary endpoint: Non-inferiority in change in HbA1c from baseline at 26 weeks, with a prespecified non-inferiority margin of 0.4%.

    Lung safety monitoring: FEV1 (forced expiratory volume in 1 second) and FVC measured at baseline, 12 weeks, and 26 weeks. Serious pulmonary adverse events tracked throughout.

    Key secondary endpoints: Weight change, treatment satisfaction (patients and parents), time in range (blood glucose 70 to 180 mg/dL), hypoglycemia frequency.

    The primary endpoint: what happened and why it matters

    This is the most clinically important and least straightforwardly reported aspect of the INHALE-1 data, and it deserves transparent presentation.

    HbA1c analysisBetween-group difference (Afrezza minus MDI)vs. 0.4% margin
    Full intent-to-treat (ITT) analysis (n=230)+0.435%Exceeds margin — non-inferiority NOT met
    Modified ITT (mITT) analysis (n=229, excluding 1 non-adherent patient)+0.370%Below margin — non-inferiority met

    Source: INHALE-1, NCT04974528. Published Diabetes Care. January 2026. Cardiology Advisor pre-approval coverage. April 2026.

    In the full ITT population, the mean HbA1c change was marginally worse in the Afrezza arm, with a between-group difference of 0.435%. This narrowly exceeded the prespecified non-inferiority margin of 0.4%, meaning the full analysis technically did not meet the primary endpoint as specified.

    According to MannKind and the investigating team, this outcome was driven by a single patient who did not adhere to the study protocol. Excluding this patient in the pre-specified mITT analysis produced a between-group difference of 0.370%, which falls within the 0.4% margin, meeting non-inferiority.

    The FDA approved Afrezza for pediatric use based on the totality of evidence, including the mITT analysis, 26-plus weeks of lung function data showing no meaningful pulmonary effects, 52-week safety extension data, and more than 20 years of Technosphere inhaled insulin research across thousands of patients including prior adult programs.

    It is worth being direct about what this means: the FDA reviewed the evidence and concluded the benefit-risk profile supports approval. The influence of a single non-adherent patient on the ITT analysis, the pre-specified nature of the mITT sensitivity analysis, and the favorable safety, satisfaction, and weight data collectively informed that conclusion. Patients and prescribers should be aware of this nuance; it does not invalidate the approval but it is relevant context for how to weigh the glycemic control evidence.

    Lung function: the key safety endpoint

    Lung function parameterAfrezza armMDI arm
    Mean FEV1 at baseline2.901 L (99.6% predicted)2.948 L (102.3% predicted)
    Mean FEV1 at week 262.934 L (96.6% predicted)2.957 L (98.0% predicted)
    Between-group difference in FEV1 changeNot statistically significantReference
    Serious pulmonary adverse eventsNone reportedNone reported
    Normal FEV1 range maintained throughoutYes, both groupsYes

    The lung function data is the most reassuring finding from INHALE-1 for families with legitimate concerns about what happens to a child’s lungs when they inhale insulin particles for months or years. In INHALE-1, both groups showed small declines in FEV1 percentage of predicted at 26 weeks, with no statistically significant difference between groups and both remaining solidly within normal range throughout.

    No serious pulmonary complications were reported in either group over 26 weeks or through the 52-week safety extension.

    Secondary endpoints: weight and satisfaction

    Secondary endpointFinding
    Weight gain at 26 weeksSignificantly less with Afrezza than MDI
    Treatment satisfaction (patient-reported)Significantly higher with Afrezza
    Parent treatment satisfactionSignificantly higher for parents of Afrezza-treated patients
    Hypoglycemia frequency at 26 weeksNo significant difference between groups

    The weight finding is clinically meaningful. Weight gain is a documented side effect of intensified insulin therapy in children and adolescents, and excess weight gain in a pediatric diabetes population has both metabolic and psychological implications. Less weight gain with equivalent glycemic control is a genuine secondary benefit.

    The treatment satisfaction finding matters for exactly the reason discussed above: a mealtime insulin option that children and parents prefer is more likely to be used consistently, particularly for the dose corrections and meal-related doses that are most commonly skipped.

    The Lung Cancer Warning: What It Means and Does Not Mean for Children

    Adults using Afrezza carry a warning about a potential lung cancer signal observed in adult clinical trials. This is a labeled warning that appears in the prescribing information and requires honest discussion.

    The signal emerged from long-term adult trials and post-market pharmacovigilance in adults with significant histories of smoking. A causal relationship between inhaled insulin use and lung cancer has not been established. The FDA’s assessment for the adult label concluded the benefit-risk profile remained favorable for indicated adult patients while warranting the warning and ongoing monitoring.

    For pediatric patients, several important contextual points apply:

    • The lung cancer signal, to the extent it exists, was observed in adults with long smoking histories
    • INHALE-1 enrolled children specifically excluding prior clinically significant pulmonary disease and requiring baseline normal lung function
    • No oncologic safety signals were observed in INHALE-1 or its extension
    • Afrezza is labeled for pediatric use starting at age 6, and the FDA reviewed pediatric-specific lung function data before granting the approval

    The warning is present in the pediatric label. Parents and prescribers should be aware of it, discuss it in the context of the full benefit-risk picture for an individual child, and continue routine follow-up monitoring of pulmonary function as clinically indicated.

    Safety: The Full Prescribing Information Picture

    Boxed warning (applies to adult label; relevant context for pediatric prescribers):

    • Acute bronchospasm in patients with chronic lung disease (asthma, COPD)
    • Contraindicated in patients with chronic lung disease
    • Lung cancer signal in adults (see above)

    Contraindications:

    • Patients with chronic lung disease including asthma and COPD (increased risk of acute bronchospasm)
    • During episodes of hypoglycemia
    • Hypersensitivity to any component of the formulation

    Warnings and precautions:

    • Acute bronchospasm: patients should have a short-acting bronchodilator available; spirometry is recommended before initiating treatment in patients with mild or moderate lung disease
    • Hypoglycemia: as with all insulins, the risk of hypoglycemia requires monitoring
    • Hypokalemia: insulin drives potassium into cells; monitor in patients at risk
    • Fluid retention and heart failure (applies to combination with thiazolidinediones, not standard pediatric use)

    Lung function monitoring: Perform FEV1 assessment before initiating Afrezza, every 6 months during treatment, and as clinically indicated.

    Who Should and Should Not Use Afrezza

    Appropriate candidates for Afrezza in the pediatric setting

    • Children and adolescents aged 6 and older with type 1 or type 2 diabetes who require mealtime insulin
    • Patients with significant needle anxiety affecting mealtime insulin adherence
    • Patients who frequently skip or reduce mealtime doses due to injection reluctance
    • Patients and families who prefer the flexibility and convenience of inhaled administration for school, social, and athletic contexts
    • Patients with normal baseline lung function per spirometry

    Contraindicated or not appropriate

    • Any patient with asthma, COPD, or other chronic pulmonary disease (absolute contraindication)
    • Patients with FEV1 below 70% predicted (exclude from eligibility per trial criteria)
    • Patients with recent respiratory tract infections (hold until resolved)
    • Patients under 6 years of age
    • Afrezza is not a replacement for basal insulin and cannot be used as a basal insulin; it is a mealtime (prandial) insulin only

    Practical note for younger patients (ages 6 to 7)

    Afrezza administration requires the ability to use the inhaler device correctly and to exhale fully before inhalation. Children aged 6 to 7 may require more practice and caregiver supervision to ensure consistent technique. Pediatric endocrinologists and diabetes educators should assess inhaler technique specifically in younger patients before transitioning to Afrezza independently.

    Dosing

    Afrezza doses are based on the patient’s usual rapid-acting insulin analog dose, converted according to the prescribing information dose conversion table. The drug is available in single-use cartridges of 4 units, 8 units, and 12 units of inhaled insulin. Key dose conversion guidance (from the January 2026 label update providing starting dose guidance for patients switching from insulin pumps or MDI) is available in the full prescribing information.

    Timing: inhale at the beginning of each meal. Do not use during or after a meal. Do not use for correction doses if the patient is already hypoglycemic.

    Access and Cost

    MannKind has announced that eligible patients can access Afrezza for $35 or less per month through its MannKind Cares patient support program. For a condition requiring daily medication for life, this cost point is a meaningful access consideration and compares favorably with list pricing for injectable rapid-acting insulin analogs prior to the insulin price cap legislation and assistance programs currently in effect.

    For related HED coverage on insulin access and recent approvals, see our post on Awiqli, the first once-weekly basal insulin for type 2 diabetes, our post on Langlara and what interchangeable insulin biosimilars mean for affordability, and our post on Linzess expanding to children as young as 2 as another pediatric label expansion approval from the same week.

    Sources

    FDA approval announcement and MannKind press release: MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes. GlobeNewswire. May 29, 2026.

    Drugs.com approval news: MannKind Announces FDA Approval of Afrezza for Children and Adolescents Aged 6 and Older. drugs.com. May 29, 2026.

    AJMC clinical summary: FDA Approves Inhaled Insulin for Children, Adolescents With Diabetes. ajmc.com. May 2026.

    Pharmacy Times approval coverage: FDA Approves Afrezza Insulin Inhalation Powder for Children, Adolescents With Type 1 and Type 2 Diabetes. pharmacytimes.com. May 2026.

    HCPLive approval coverage: FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes. hcplive.com. May 2026.

    Patient Care Online: FDA Approves First Inhaled Mealtime Insulin for Children and Adolescents With Diabetes. patientcareonline.com. May 2026.

    TechTimes decision day coverage (with primary endpoint nuance): Inhaled Insulin for Children: FDA Reaches Decision Deadline for Afrezza. techtimes.com. May 29, 2026.

    INHALE-1 primary publication: INHALE-1 Phase 3 results. Diabetes Care. January 2026.

    INHALE-1 ADA 2025 presentation: Phase 3 INHALE-1 results presented at 85th ADA Scientific Sessions. Chicago, June 2025.

    INHALE-1 trial registration: NCT04974528. ClinicalTrials.gov.

    sBLA acceptance (October 2025): MannKind Announces US FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years. GlobeNewswire. October 13, 2025.

    Cardiology Advisor pre-approval detailed data summary: FDA Drug Approval Decisions Expected in May 2026. thecardiologyadvisor.com. April 2026.

    Afrezza original adult FDA approval (June 2014): FDA approves Afrezza to treat diabetes. FDA.gov. June 2014.

    Afrezza prescribing information: Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind. 2026.

    Needle anxiety and pediatric diabetes: Fear of Needles and Its Impact on Diabetes Management. PMC8261965.

    Diabetic complications prevention: Preventing Diabetes Problems. NIDDK.

    Patient resources: JDRF (type 1 diabetes) | American Diabetes Association: Mealtime Insulin | MannKind Cares patient support | Afrezza patient website

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Afrezza is contraindicated in patients with chronic lung disease including asthma and COPD. All decisions about mealtime insulin therapy for children and adolescents with diabetes should be made in close consultation with a pediatric endocrinologist or diabetes care team familiar with the child’s complete health history, current diabetes management, and pulmonary function status.

  • Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    📌 The essentials On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib, Incyte), a once-daily extended-release formulation of ruxolitinib, for the same four indications as the original Jakafi: intermediate- or high-risk myelofibrosis (MF) in adults, polycythemia vera (PV) in adults with inadequate response to or intolerance of hydroxyurea, steroid-refractory acute graft-versus-host disease (GVHD) in adults and pediatric patients aged 12 and older, and chronic GVHD after failure of 1 or 2 lines of systemic therapy in adults and pediatric patients aged 12 and older. This is a new dosage form approval, not a new indication. The indications are identical to the original Jakafi. The clinical basis: a randomized, open-label, 2-period, 2-way crossover bioequivalence study (NCT06555081) in 169 healthy adults, showing that 55 mg Jakafi XR once daily is bioequivalent to 25 mg Jakafi twice daily based on steady-state pharmacokinetic measures. Results presented as an ASH 2025 poster (Gong et al. Blood. 2025;146(suppl 1):5045). Safety of Jakafi XR is established from the extensive controlled studies of the original Jakafi across all approved indications: no new safety signals. Available for pharmacy orders beginning May 8, 2026. Critical practical note: Jakafi XR is not a new drug. It delivers the same ruxolitinib molecule at equivalent systemic exposure in a single daily tablet instead of two. Patients who switch should not expect a different clinical effect; the therapeutic benefit comes from the same mechanism and the same total daily drug exposure.

    Patients with myelofibrosis, polycythemia vera, and graft-versus-host disease have been managing chronic conditions for years on a twice-daily regimen. Twice daily means twice daily: morning and evening, 12 hours apart, building those doses into the rhythm of every single day. For patients who are also managing multiple comorbidities with multiple medications, that twice-daily requirement is one of many adherence demands that can compound into a real burden over time.

    On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib), a once-daily extended-release formulation of a drug that has been the standard of care for myelofibrosis and polycythemia vera since 2011 and for steroid-refractory GVHD since 2019 and 2021. The clinical evidence behind the original Jakafi is unchanged. The new formulation simply delivers the same drug at equivalent systemic exposure in a single morning tablet.

    This is not a clinical advance in the sense of a new drug with new efficacy data. It is a formulation advance, removing one daily dose from the schedule of patients who are likely to be on this drug for years.

    What Ruxolitinib Is and Why These Three Conditions Require Long-Term Treatment

    Ruxolitinib is a selective inhibitor of Janus kinase 1 (JAK1) and JAK2, two enzymes that are central to the signaling pathways mediating inflammatory cytokine responses and hematopoietic cell proliferation. JAK1 and JAK2 mediate signaling from multiple cytokine receptors, and their overactivation is the pathological driver in myelofibrosis, polycythemia vera, and GVHD through distinct but related mechanisms.

    Understanding why patients take ruxolitinib for extended periods requires understanding each of the conditions it treats.

    Myelofibrosis

    Myelofibrosis is a myeloproliferative neoplasm in which progressive bone marrow scarring (fibrosis) disrupts normal blood cell production. The fibrosis is driven by inflammatory cytokine overproduction mediated in large part through JAK-STAT pathway activation, often involving somatic mutations in JAK2, CALR, or MPL. The result is progressive anemia, enlargement of the spleen (splenomegaly), constitutional symptoms including debilitating fatigue, night sweats, and weight loss, and over time, the risk of transformation to acute leukemia.

    Ruxolitinib was the first approved therapy to substantially reduce splenomegaly and improve constitutional symptoms in intermediate- and high-risk MF. It does not typically reverse or halt fibrosis progression, but it durably reduces the inflammatory burden that drives many of the disease’s most disabling manifestations. Most patients with MF who respond to ruxolitinib continue it indefinitely, as disease symptoms return on discontinuation.

    Polycythemia vera

    Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by overproduction of red blood cells, often accompanied by elevated white blood cells and platelets, driven almost universally by the JAK2 V617F mutation. The primary risk is thrombosis: the abnormally high blood cell counts and viscosity substantially elevate the risk of stroke, deep vein thrombosis, pulmonary embolism, and other thrombotic events. First-line management involves phlebotomy and aspirin for low-risk patients, and hydroxyurea for high-risk patients. Ruxolitinib is indicated for patients who have had an inadequate response to or are intolerant of hydroxyurea, providing JAK2-targeted suppression of the malignant clone. Again, this is chronic therapy: patients who achieve hematocrit control and symptom relief on ruxolitinib continue it as long as it is effective and tolerated.

    Graft-versus-host disease

    GVHD is a complication of allogeneic stem cell transplantation in which donor immune cells attack the recipient’s tissues. Acute GVHD typically involves the skin, liver, and gastrointestinal tract; chronic GVHD can affect virtually any organ system and is associated with significant morbidity and mortality. Ruxolitinib, by inhibiting JAK-mediated inflammatory cytokine signaling in donor T cells, reduces the inflammatory cascade driving tissue damage. GVHD patients may require treatment for months to years, again placing this in the category of chronic therapy where dosing schedule matters.

    Why a once-daily formulation matters for chronic blood disease management Patients with MF, PV, and GVHD are frequently older adults with multiple conditions managing multiple daily medications. They may also be managing disease symptoms including fatigue, pain, and cytopenias that affect daily function. In this context, the psychosocial and practical dimension of medication burden is well-documented: adherence to twice-daily regimens is consistently lower than once-daily regimens across all chronic disease areas, even when patients understand the clinical importance of each dose. Studies in conditions from hypertension to HIV have shown that reducing dosing frequency from twice daily to once daily improves adherence by 10 to 20%, with downstream improvements in outcomes that compound over years of treatment. For a drug that works as long as it is taken and loses its effect when stopped, that adherence difference is clinically meaningful.

    The Approval Basis: What Bioequivalence Means and Why It Is the Right Standard Here

    The FDA approved Jakafi XR based on a bioequivalence study, not on a new Phase 3 efficacy trial. This is the correct regulatory approach for a new dosage form of an existing drug with well-established efficacy and safety. Understanding why requires understanding what bioequivalence means and what it does not.

    What the bioequivalence study showed

    The pivotal study (NCT06555081) was a randomized, open-label, 2-period, 2-way crossover study in 169 healthy adult participants. Each participant received both Jakafi XR 55 mg once daily and Jakafi 25 mg twice daily in random order, with a washout period between. The study measured key pharmacokinetic parameters at steady state: AUC (area under the concentration-time curve, measuring total drug exposure) and Cmax (peak drug concentration).

    The FDA’s standard for bioequivalence requires that the 90% confidence interval for the ratio of the test (XR) to reference (IR) geometric means for AUC and Cmax falls within 80 to 125%. Jakafi XR met these criteria, confirming that the once-daily extended-release formulation delivers the same total daily ruxolitinib exposure as the twice-daily immediate-release formulation.

    Results were presented at the 2025 American Society of Hematology Annual Meeting (ASH 2025) in a poster by Gong et al. (Blood. 2025;146(suppl 1):5045).

    Pharmacokinetic differences between XR and IR: what matters clinically The extended-release mechanism produces a different concentration-time profile than immediate release, even when total daily exposure is equivalent. Jakafi IR produces two peak concentrations per day (one after each dose) with a trough in between. Jakafi XR produces a single, broader, lower peak with more consistent drug levels throughout the 24-hour dosing interval. For JAK inhibition, which requires sustained target coverage rather than intermittent high-concentration peaks, the flatter pharmacokinetic profile of once-daily XR is biologically appropriate. The trough concentrations between IR doses might theoretically allow partial JAK pathway reactivation; the XR formulation maintains steadier JAK inhibition. Whether this translates into any measurable clinical difference in efficacy or tolerability is not yet established from comparative clinical trial data, but the pharmacological rationale supports the XR approach.

    Why no new Phase 3 trial was required

    Ruxolitinib has been studied in multiple large Phase 3 trials across all approved indications, involving thousands of patients with substantial follow-up. The COMFORT-I and COMFORT-II trials established its efficacy in MF; RESPONSE trials established its efficacy in PV; REACH2 and REACH3 established its efficacy in acute and chronic GVHD respectively. Requiring a new Phase 3 trial to approve a formulation change that delivers identical drug exposure would delay access to the more convenient dosing form without generating scientifically useful information. The FDA’s bioequivalence pathway is precisely designed for this scenario.

    The Full Jakafi/Jakafi XR Approved Indication Picture

    Both Jakafi (original, twice daily) and Jakafi XR (extended release, once daily) now carry the same four indications:

    IndicationPopulation
    Intermediate- or high-risk myelofibrosis (primary MF, post-PV MF, post-ET MF)Adults
    Polycythemia vera with inadequate response to or intolerance of hydroxyureaAdults
    Steroid-refractory acute GVHDAdults and pediatric patients aged 12 and older
    Chronic GVHD after failure of 1 or 2 lines of systemic therapyAdults and pediatric patients aged 12 and older

    Jakafi XR is not approved for use in children with MF or PV; the MF and PV indications are adults only, identical to the original formulation. The GVHD indications cover pediatric patients aged 12 and older with the same weight and age constraints as the original formulation.

    Safety: What Applies to Jakafi XR

    Because Jakafi XR delivers the same drug at the same systemic exposure, its safety profile is established from the extensive clinical trial database of the original Jakafi across all approved indications. There are no new safety signals from Jakafi XR; the known adverse event profile of ruxolitinib applies in full.

    Most important safety considerations for prescribers and patients:

    Cytopenias: Thrombocytopenia, anemia, and neutropenia are the most common adverse reactions and can be severe. Dose adjustment or temporary interruption may be required based on complete blood count results. Monitoring is required before initiating and regularly during treatment.

    Serious infections: Ruxolitinib increases the risk of serious bacterial, mycobacterial, fungal, and viral infections. Tuberculosis reactivation has been reported. Patients should be evaluated for TB before starting treatment. Progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by JC virus, has been reported rarely with ruxolitinib. Monitoring for signs and symptoms of new neurological symptoms is important.

    Herpes zoster: Reactivation of varicella zoster virus (shingles) occurs at higher rates with ruxolitinib than with many other agents. Varicella zoster vaccination before initiating treatment is recommended where possible.

    Second primary malignancies: Non-melanoma skin cancers and lymphomas have been reported. Periodic skin examinations are recommended.

    Lipid elevations: Increases in cholesterol, LDL, and triglycerides have been reported. Assess lipid levels approximately 8 to 12 weeks after initiating treatment.

    Symptom exacerbation on discontinuation: Abrupt discontinuation or dose reduction of ruxolitinib in MF patients can cause rapid return of splenomegaly, constitutional symptoms, and in rare cases a syndrome resembling hemophagocytic lymphohistiocytosis (HLH). Dose tapering is recommended when discontinuation is necessary.

    Boxed warning: The FDA requires a boxed warning for thrombosis including fatal cases and for serious infections. These risks apply identically to Jakafi XR as to the original Jakafi.

    Dosing: The Key Dose Correspondence Table

    Jakafi XR doses correspond to Jakafi (immediate-release) doses at a 2.2:1 ratio reflecting the once-daily to twice-daily conversion. The standard approved correspondence is:

    Jakafi XR (once daily)Equivalent Jakafi IR doseClinical context
    55 mg once daily25 mg twice dailyStandard MF/PV dose; bioequivalence study dose
    Other XR dosesCorresponding IR twice-daily dosesPer prescribing information; dose adjustments mirror IR guidance

    Administration: Take Jakafi XR orally once daily at approximately the same time each day, with or without food. Swallow tablets whole; do not crush, chew, or split. If a dose is missed, take it as soon as possible on the same day; if the next day has arrived, skip the missed dose.

    Switching from Jakafi IR to Jakafi XR: Patients who are stable on Jakafi IR can switch to the corresponding Jakafi XR dose. No dose change is required; the XR dose that matches their current total daily IR exposure should be used. Because switching does not change drug exposure, no transition period or observation period beyond clinical routine is needed.

    Practical Implications: Who Benefits Most From the Switch

    Not every patient currently on Jakafi needs to switch to Jakafi XR. The clinical effect will be the same. The question is whether once-daily dosing offers enough practical benefit for a given patient to justify the conversation with their hematologist and the pharmacy change.

    Most likely to benefit from switching:

    • Patients who find twice-daily adherence difficult due to variable daily schedules, work constraints, or fatigue affecting evening dose reliability
    • Patients who are managing multiple twice-daily medications and for whom consolidating to once-daily simplifies overall regimen complexity
    • Newly initiating patients for whom once-daily is operationally simpler than twice-daily from the outset
    • Patients who have expressed frustration with the twice-daily scheduling burden to their hematologist

    Unlikely to need switching:

    • Patients who are well-established on Jakafi IR with no adherence concerns
    • Patients for whom the twice-daily timing provides useful structure or reminders anchored to established daily routines

    The key message for patients and clinicians is that Jakafi XR is not a better drug than Jakafi. It is the same drug with a more convenient schedule. In a chronic condition where medication duration is measured in years, a more convenient schedule is a genuine quality-of-life improvement for patients who want it.

    For related HED coverage of other formulation advances improving treatment convenience in chronic conditions, see our post on Awiqli, the first once-weekly basal insulin, which similarly reduced the injection frequency from 365 times per year to 52 for appropriate patients with type 2 diabetes.

    Sources

    FDA approval announcement: FDA approves ruxolitinib extended-release tablets (Jakafi XR). FDA.gov. May 1, 2026.

    Incyte press release: Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets. businesswire.com. May 1, 2026.

    Drugs.com approval news: Incyte Announces FDA Approval of Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD. drugs.com. May 2026.

    OncLive clinical coverage: FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis, Polycythemia Vera, and GVHD. onclive.com. May 2026.

    Targeted Oncology coverage: FDA Approves Extended-Release Ruxolitinib Once-Daily for MPNs and GVHD. targetedonc.com. May 2026.

    Cancer Therapy Advisor clinical review: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. cancertherapyadvisor.com. May 2026.

    CancerNetwork: FDA Approves Ruxolitinib Tablets for Hematologic Malignancies. cancernetwork.com. May 2026.

    CURE magazine coverage: FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions. curetoday.com. May 2026.

    Hematology Advisor: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. hematologyadvisor.com. May 2026.

    ASH 2025 bioequivalence poster: Gong X, Xun Z, Getsy J, McGee R, Mondick J, Punwani N. Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults. Blood. 2025;146(suppl 1):5045. doi:10.1182/blood-2025-5045

    Bioequivalence study registration: NCT06555081. ClinicalTrials.gov.

    Jakafi original FDA approval (2011): FDA approves ruxolitinib for myelofibrosis. FDA.gov. November 2011.

    Jakafi prescribing information: Jakafi XR (ruxolitinib) Prescribing Information. Incyte Corporation. 2026.

    FDA bioequivalence guidance: Bioequivalence Studies with Pharmacokinetic Endpoints. FDA.gov.

    Ruxolitinib mechanism overview: Ruxolitinib. StatPearls. NCBI.

    JAK-STAT pathway in MPNs: JAK-STAT Pathway in Myeloproliferative Neoplasms. PMC4207474.

    MF cancer overview: Myelofibrosis. American Cancer Society.

    PV overview: Polycythemia Vera. NHLBI.

    GVHD overview: GVHD Fact Sheet. NCI.

    Patient resources: MPN Research Foundation | Leukemia and Lymphoma Society: Myelofibrosis | National MPN Advocacy and Education | Bone Marrow Transplant Info Network

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about switching from Jakafi to Jakafi XR, or initiating ruxolitinib therapy in any approved indication, should be made in consultation with a qualified hematologist familiar with the patient’s full clinical history, current blood counts, and concurrent medications. Do not discontinue or change ruxolitinib doses without medical guidance.
  • A Rare Bile Duct Cancer Defined by a Single Gene Fusion Just Got Its First Approved Targeted Therapy. Here Is What Bizengri Is and What the eNRGy Trial Shows.

    A Rare Bile Duct Cancer Defined by a Single Gene Fusion Just Got Its First Approved Targeted Therapy. Here Is What Bizengri Is and What the eNRGy Trial Shows.

    📌 The essentials On May 8, 2026, the FDA approved Bizengri (zenocutuzumab-zbco, Partner Therapeutics) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This is the first FDA-approved targeted therapy specifically for NRG1 fusion-positive (NRG1+) cholangiocarcinoma. Bizengri’s third approved indication: it was previously approved in December 2024 for NRG1+ non-small cell lung cancer and NRG1+ pancreatic adenocarcinoma. Bizengri is now the only approved therapy for NRG1+ solid tumors across three different cancer types. The approval was expedited by a Commissioner’s National Priority Voucher (CNPV), awarded May 6, 2026 and used to compress the review timeline. The clinical basis: Phase 1/2 eNRGy trial (NCT02912949), cholangiocarcinoma cohort of 19 evaluable patients. ORR: 36.8% (95% CI 16.3 to 61.6%). Duration of response: 2.8 to 12.9 months. Regulatory designations: Breakthrough Therapy Designation (October 2025), Orphan Drug Designation (February 2026). Critical testing requirement: NRG1 fusions must be detected using comprehensive molecular testing, specifically tissue-based RNA sequencing, to reliably identify eligible patients. DNA-based testing alone may miss NRG1 fusions. Dosing: 750 mg IV every 2 weeks.

    Cholangiocarcinoma, commonly called bile duct cancer, is an aggressive malignancy arising from the epithelial cells lining the bile ducts. It is rare, accounting for approximately 3% of all gastrointestinal cancers globally, but deadly: the five-year survival rate for metastatic disease is below 10%, and most patients are diagnosed at stages where surgery is not possible.

    The treatment landscape for cholangiocarcinoma has evolved rapidly in recent years. Several actionable molecular targets have been identified in subsets of the disease, including FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, HER2 amplification, and now NRG1 fusions. Each molecular subset represents a small fraction of the total cholangiocarcinoma population, but targeted therapy for each has produced response rates substantially higher than chemotherapy alone in those patients who carry the specific molecular alteration.

    On May 8, 2026, patients with NRG1 fusion-positive cholangiocarcinoma gained their first approved targeted option. Bizengri (zenocutuzumab-zbco), a bispecific antibody targeting HER2 and HER3, was approved based on a 36.8% objective response rate in 19 evaluable patients in the eNRGy trial cholangiocarcinoma cohort. In a disease with no prior approved targeted therapy for this molecular subset, that number represents a clinically meaningful new option for a population that has had very few.

    What NRG1 Fusions Are and Why They Matter Across Multiple Cancers

    To understand why Bizengri works across NSCLC, pancreatic cancer, and now cholangiocarcinoma, it helps to understand what an NRG1 fusion is and what biological pathway it activates.

    The NRG1 gene and neuregulin signaling

    NRG1 (neuregulin 1) encodes a family of growth factor proteins called neuregulins that are ligands for HER3 (ErbB3), a member of the HER receptor tyrosine kinase family. When neuregulin 1 binds HER3, it triggers HER3 to heterodimerize preferentially with HER2 (ErbB2), forming a signaling complex that activates downstream proliferation and survival pathways including PI3K/AKT and MAPK/ERK.

    In normal tissue, NRG1 signaling through HER3/HER2 is tightly regulated and context-dependent. In cancers with NRG1 gene fusions, the NRG1 coding sequence is joined to the sequence of a partner gene, creating a fusion protein that is expressed at abnormally high levels, constitutively activates HER3/HER2 signaling, and drives cancer cell proliferation in a fusion-dependent manner.

    NRG1 fusions are found across multiple solid tumor types but are rare in each individual cancer: prevalence estimates of approximately 0.2% of all solid tumors, with higher rates in certain histologies. In cholangiocarcinoma, NRG1 fusions are estimated to occur in approximately 1 to 2% of cases, representing a very small molecular subset of an already rare cancer. In the United States, this translates to only a few hundred patients per year.

    The testing challenge: why DNA sequencing alone may miss NRG1 fusions NRG1 fusions are gene rearrangements that join introns of two different genes. Because the fused protein is produced from the rearranged mRNA rather than from a simple point mutation or small insertion/deletion, RNA-based sequencing (which reads transcribed mRNA) detects NRG1 fusions more reliably than standard DNA-based next-generation sequencing. Partner Therapeutics specifically noted in the approval documentation that comprehensive molecular testing, particularly tissue-based RNA sequencing, is essential to reliably detect NRG1 fusions and identify eligible patients. Oncologists managing cholangiocarcinoma patients should ensure that their molecular profiling platform includes RNA-based fusion detection, as DNA sequencing alone may produce false-negative results. This is a critical testing consideration that distinguishes NRG1 fusion detection from some other molecular targets in oncology.

    What Zenocutuzumab Is and How It Works

    Zenocutuzumab (brand name Bizengri) is a bispecific antibody, meaning it is engineered to bind two different molecular targets simultaneously. Specifically, it targets both HER2 and HER3 simultaneously using a single antibody molecule. This dual targeting is the key to its mechanism in NRG1 fusion-positive tumors.

    The mechanism of action exploits a specific vulnerability in NRG1 fusion-driven cancer cells:

    In NRG1+ tumors, the fusion protein acts as an overexpressed HER3 ligand, continuously stimulating HER3 on the cancer cell surface to heterodimerize with HER2. Zenocutuzumab blocks this process by binding both HER3 and HER2 simultaneously: its HER3-binding arm prevents the NRG1 fusion protein from docking with HER3, while its HER2-binding arm prevents HER2 from forming its signaling-competent heterodimer with HER3. The result is that the constitutive NRG1 fusion-driven HER3/HER2 signaling loop is interrupted at two points simultaneously.

    This dual blockade strategy is mechanistically rational for NRG1 fusion-driven tumors in a way that single-target approaches are not. Blocking only HER3 might be insufficient if HER2 can still be activated by other means; blocking both removes the substrate and the dimerization partner of the constitutively active signaling complex.

    Zenocutuzumab does not work in tumors where HER2/HER3 signaling is activated by HER2 gene amplification or overexpression rather than NRG1 fusion. Its mechanism requires the NRG1 fusion to be the driver. This is why patient selection by molecular testing is not optional but essential for appropriate use.

    Bizengri’s Three Approved Indications: A Tumor-Agnostic Approach to a Single Molecular Target

    Bizengri is now approved across three cancer types defined by the same molecular alteration:

    IndicationApproval dateSetting
    NRG1+ non-small cell lung cancerDecember 4, 2024After prior systemic therapy
    NRG1+ pancreatic adenocarcinomaDecember 4, 2024After prior systemic therapy
    NRG1+ cholangiocarcinoma (biliary tract)May 8, 2026After prior systemic therapy

    This approval strategy, using one molecular biomarker to justify approval across histologically distinct cancers, is the definition of a tumor-agnostic or biomarker-driven approach. The NRG1 fusion is the target, and the tissue of origin is secondary. This pattern follows the FDA’s broader shift toward molecular rather than anatomical cancer classifications, exemplified by earlier tumor-agnostic approvals such as pembrolizumab for MSI-H/dMMR tumors and larotrectinib for TRK fusion-positive cancers.

    The CNPV connection is also relevant here. For related coverage of how the CNPV program has been used to accelerate approvals for other conditions in 2026, see our post on the FDA’s fast-tracking of psychedelic drug programs for mental illness and our post on the first gene therapy for genetic deafness, the first gene therapy approved under CNPV.

    The eNRGy Trial Cholangiocarcinoma Cohort: What the Evidence Shows

    Trial design

    eNRGy (NCT02912949) is a Phase 1/2, open-label, registrational, multicenter basket trial evaluating zenocutuzumab across multiple solid tumor types harboring NRG1 fusions. The basket design is appropriate for rare molecular alterations that appear across multiple histologies: rather than running a separate trial for each tumor type, a single trial enrolls all patients with the molecular target regardless of where the cancer originated.

    The cholangiocarcinoma cohort enrolled patients with advanced, unresectable or metastatic cholangiocarcinoma harboring NRG1 gene fusions whose disease had progressed on or after prior systemic therapy. NRG1 fusion status was required to be confirmed by molecular testing.

    Efficacy results

    OutcomeCholangiocarcinoma cohort (n=19 evaluable)
    Overall response rate (ORR)36.8% (95% CI 16.3 to 61.6%)
    Number of confirmed responders7 of 19 patients
    Duration of responseRange: 2.8 to 12.9 months
    Assessment methodRECIST v1.1, blinded independent central review

    Source: FDA approval, May 8, 2026. Presented at AACR/NCI/EORTC Conference on Molecular Targets and Cancer Therapeutics, October 2025, Boston.

    Interpreting the results in context

    A 36.8% ORR in a 19-patient cohort must be understood within the context of several important facts.

    The denominator is tiny because the disease is rare. NRG1 fusion-positive cholangiocarcinoma affects only an estimated few hundred Americans per year. Running a trial large enough to power a survival analysis in this population would take many years and deny patients in the interim a therapy that is producing clinically meaningful responses. The FDA’s standard for approvals in ultra-rare molecularly defined cancers appropriately accounts for this constraint.

    The comparator context is chemotherapy. Historically, patients with advanced cholangiocarcinoma whose disease has progressed after first-line therapy have had very limited options with response rates in the range of 5 to 15% to second-line chemotherapy. A 36.8% ORR against this background represents a meaningfully differentiated result.

    The basket trial precedent is established. The NSCLC and pancreatic cancer approvals from December 2024 were based on the same eNRGy trial using the same basket design. In the NSCLC cohort (n=30), the ORR was 33% with a median duration of response of 7.4 months. In the pancreatic cohort (n=30), the ORR was 40% with a median duration of 5.9 months. The cholangiocarcinoma ORR of 36.8% is consistent with the pattern observed across tumor types in this molecular subset, further supporting the NRG1 fusion as a clinically actionable driver across histologies.

    Why small basket trial cohorts are acceptable for molecular-rare cancers The FDA’s framework for tumor-agnostic and rare molecular alteration approvals recognizes that conventional large randomized trial design is not feasible when the target population may number in the hundreds rather than thousands. The standard applied is whether the evidence is clinically meaningful and sufficiently robust to support a reliable benefit-risk assessment. For Bizengri in NRG1+ cholangiocarcinoma, the 36.8% ORR from a prospectively conducted, centrally reviewed cohort in a registrational basket trial, in a disease with no approved targeted therapy and historically poor response to chemotherapy, meets this standard. The approval was also supported by the mechanistic coherence of responses across three tumor types in the same trial, which substantially strengthens the interpretation of the cholangiocarcinoma cohort data.

    Safety

    The safety profile of zenocutuzumab in the cholangiocarcinoma cohort was consistent with its established profile across other NRG1+ tumor types in eNRGy.

    Common adverse reactions (consistent with class and mechanism): infusion-related reactions, fatigue, nausea, diarrhea, musculoskeletal pain, decreased appetite.

    Serious adverse reactions: Serious infusion-related reactions can occur and require premedication per the prescribing information and monitoring during each infusion.

    Left ventricular dysfunction: HER2-targeting antibodies carry a class risk of cardiotoxicity including left ventricular dysfunction and decreased ejection fraction. Monitor cardiac function per prescribing information. Patients with pre-existing significant cardiac disease require careful evaluation before initiating treatment.

    Embryo-fetal toxicity: Zenocutuzumab targets HER2 and HER3, growth factor receptors that play roles in fetal development. Females of reproductive potential should use effective contraception during treatment and for 7 months after the last dose. Males should use effective contraception during treatment and for 4 months after the last dose.

    For the complete adverse event profile and dose modification guidance, the full prescribing information should be reviewed before initiating treatment.

    Dosing and Administration

    ParameterDetails
    Dose750 mg intravenous infusion
    ScheduleEvery 2 weeks (14-day cycle)
    PremedicationPer prescribing information before each infusion
    SettingHealthcare facility capable of managing infusion reactions
    Continue untilDisease progression or unacceptable toxicity

    The CNPV Connection: How the Approval Was Expedited

    The Bizengri cholangiocarcinoma approval used the Commissioner’s National Priority Voucher (CNPV) program for the first time in an oncology/rare cancer setting. The CNPV was awarded to Partner Therapeutics on May 6, 2026, and the FDA approved the cholangiocarcinoma indication just two days later on May 8, 2026. The CNPV compressed the standard review timeline by applying priority review resources immediately, accelerating access to a therapy for a population with urgent unmet need.

    The CNPV’s use in NRG1+ cholangiocarcinoma reflects the FDA’s recognition that rare molecular subsets of aggressive cancers can represent conditions of national health significance warranting the same acceleration tools applied to other priority public health areas.

    What This Means for Patients and Clinicians

    For patients with cholangiocarcinoma

    If you have been diagnosed with cholangiocarcinoma and your tumor has not yet been tested for NRG1 fusions, this approval is a reason to discuss molecular testing with your oncologist. NRG1 fusions are rare in this cancer type, but they are actionable: if present, Bizengri is now an FDA-authorized option after disease progression on prior systemic therapy.

    Comprehensive molecular testing platforms that include RNA-based fusion detection are available at major academic centers and through commercial laboratory services. Testing requirements and ordering should be discussed with your oncologist.

    For oncologists managing cholangiocarcinoma

    The approval of zenocutuzumab completes a third actionable molecular subset for cholangiocarcinoma (alongside FGFR2 fusions, IDH1 mutations, and HER2 amplification/overexpression). Comprehensive molecular profiling including RNA-based sequencing at the time of diagnosis or upon progression is increasingly essential for identifying all available targeted options.

    For patients whose NRG1 fusion status has not been determined, RNA sequencing should be requested specifically if standard next-generation sequencing panels are DNA-only. NRG1 fusions may be underdetected in DNA-based panels due to their intronic structure.

    Clinical trial opportunities

    Additional clinical development of zenocutuzumab in earlier lines and in combination regimens is ongoing. ClinicalTrials.gov and ClinicalTrials.gov for zenocutuzumab broadly list currently enrolling studies for patients interested in investigational options.

    The Cholangiocarcinoma Foundation is the leading U.S. patient advocacy organization for bile duct cancer and maintains current information on approved therapies, clinical trials, and specialist referral resources. The American Liver Foundation and NCI cholangiocarcinoma information provide clinical and research overviews.

    For related HED coverage of other molecularly targeted oncology approvals, see our post on Lifyorli (relacorilant) and the novel cortisol-resistance mechanism in platinum-resistant ovarian cancer and our post on Datroway (datopotamab deruxtecan) achieving its third approved indication in triple-negative breast cancer.

    Sources

    FDA approval announcement: FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma. FDA.gov. May 8, 2026.

    Partner Therapeutics press release: Partner Therapeutics Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher. partnertx.com. May 11, 2026.

    CNPV award press release: Partner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for Bizengri in NRG1 Fusion-Positive Cholangiocarcinoma. drugs.com. May 6, 2026.

    CancerNetwork clinical coverage: FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy. cancernetwork.com. May 2026.

    Targeted Oncology clinical coverage: FDA Approves Zenocutuzumab for NRG1 Fusion-Positive Cholangiocarcinoma. targetedonc.com. May 2026.

    PharmExec approval coverage: FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma. pharmexec.com. May 2026.

    ONS clinical summary: FDA Approves Zenocutuzumab-Zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma. ons.org. May 2026.

    eNRGy trial registration: NCT02912949. ClinicalTrials.gov.

    Bizengri original FDA approval (NSCLC/pancreas, December 2024): FDA approves zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. FDA.gov. December 2024.

    AACR/NCI/EORTC 2025 CCA presentation: Schram AM, Cleary JM, Arnold D, et al. Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: analysis from the phase 2 eNRGy trial. Presented at AACR/NCI/EORTC Conference, October 2025, Boston.

    NRG1 and HER signaling review: NRG1-HER3 signaling in cancer. PMC7297124.

    Zenocutuzumab mechanism: Bispecific antibodies targeting HER2/HER3. PMC9891442.

    NRG1 gene: NRG1 gene. NCBI.

    Cholangiocarcinoma overview: Bile Duct Cancer. American Cancer Society.

    FDA tumor-agnostic drug approvals: Tumor Agnostic Approvals. FDA.gov.

    CNPV program: Commissioner’s National Priority Voucher. FDA.gov.

    Breakthrough Therapy Designation: Breakthrough Therapy. FDA.gov.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    Patient resources: Cholangiocarcinoma Foundation | American Liver Foundation: Bile Duct Cancer | NCI Cholangiocarcinoma | ClinicalTrials.gov: zenocutuzumab

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for cholangiocarcinoma, including molecular testing decisions and therapy selection, should be made in consultation with a qualified oncologist experienced in biliary tract malignancies. Molecular testing for NRG1 fusions requires appropriate RNA-based sequencing; consult your oncologist about which testing platform is appropriate.
  • The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    📌 The essentials On May 8, 2026, the FDA approved Ocrevus (ocrelizumab, Genentech) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10 years and older who weigh at least 25 kg (approximately 55 pounds). This is Ocrevus’s first pediatric indication, expanding its label beyond adults. Ocrevus becomes only the second FDA-approved disease-modifying therapy for pediatric RRMS, after fingolimod (Gilenya, Novartis), and the first approved high-efficacy anti-CD20 therapy for this population. The clinical basis: Phase 3 OPERETTA 2 trial (NCT05123703), 187 pediatric patients aged 10 to 17 years with RRMS, randomized double-blind comparison of ocrelizumab versus fingolimod. Primary endpoint: ocrelizumab was non-inferior to fingolimod in reducing annualized relapse rate. MRI superiority: 48% reduction in new or enlarging T2 lesions (p=0.001) and 87% reduction in gadolinium-enhancing T1 lesions (p=0.001) versus fingolimod. Safety: no adverse events led to treatment withdrawal in the ocrelizumab arm. How it is given: 600 mg intravenous infusion every 24 weeks (same dose and schedule as adults). Weight minimum: the drug is not known to be safe or effective in children under 10 years of age or weighing less than 25 kg.

    Multiple sclerosis in children and adolescents is a different clinical scenario than most people picture when they think of MS. Pediatric-onset MS (POMS) represents approximately 3 to 5% of all MS cases globally, with an estimated 5,000 to 10,000 children and adolescents affected in the United States. The condition is not mild: children with POMS typically have higher relapse rates than adults, more rapid accumulation of new brain lesions on MRI, and a relapsing disease course in the vast majority of cases. What they have historically had is very few approved treatment options.

    Until May 8, 2026, fingolimod (Gilenya) was the only FDA-approved disease-modifying therapy for pediatric RRMS, a status it has held since its pediatric approval in 2018. Every other MS treatment used in children and adolescents was prescribed off-label, without the clinical trial evidence base that formal approval requires.

    That changed when the FDA approved Ocrevus (ocrelizumab) for RRMS in patients aged 10 and older, based on the Phase 3 OPERETTA 2 trial. For the first time, a high-efficacy anti-CD20 B-cell depleting therapy is formally available for pediatric patients who have not responded adequately to first-line agents or whose disease activity warrants a more aggressive approach from the start.

    What Pediatric-Onset Multiple Sclerosis Is and Why Treatment Is Urgent

    Pediatric-onset MS is defined as MS with symptom onset before age 18. Children and adolescents with POMS experience the same types of episodes as adults, including optic neuritis, limb weakness, sensory disturbance, brainstem and cerebellar dysfunction, and cognitive slowing. But several features distinguish POMS from typical adult-onset disease.

    Higher initial disease activity: Children with POMS typically have higher relapse rates than adult patients early in the disease course. Brain MRI at diagnosis often shows extensive T2 lesion burden. The inflammatory activity is often vigorous, reflecting the heightened immune responsiveness of the developing immune system.

    Predominantly relapsing course: Nearly all pediatric MS cases are relapsing-remitting, not progressive, at onset. This is both a prognostic advantage (the disease course is more amenable to disease modification) and a treatment priority (relapses in developing brains carry distinct risks for cognitive and neurological development that are not fully quantified in adults).

    Cognitive burden: Cognitive impairment is documented in a substantial proportion of children with MS, affecting processing speed, attention, memory, and executive function. Because POMS occurs during a critical period of brain development and education, the impact of unchecked disease activity on long-term cognitive trajectory is a distinct and serious concern.

    Long disease duration ahead: A child diagnosed at age 12 faces potentially decades of living with MS before the disease is biologically comparable to someone diagnosed at 50. The cumulative burden of every avoided relapse, every suppressed lesion, and every year of preserved neurological function compounds over that longer horizon.

    Why fingolimod was the only approved option for so long, and what its limitations are Fingolimod (Gilenya) was the first FDA-approved MS therapy for pediatric patients, receiving its pediatric RRMS approval in May 2018 based on the Phase 3 PARADIGMS trial. It works by sequestering lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing inflammation. It is effective and its oral administration is an advantage for younger patients. But it carries significant safety concerns: a first-dose cardiac monitoring requirement (due to the risk of bradycardia and heart block), risk of serious infections including PML and cryptococcal meningitis, varicella zoster reactivation, and ophthalmologic monitoring requirements for macular edema. In a pediatric population, these monitoring requirements represent a real burden on families, schools, and clinical teams. Until OPERETTA 2, the absence of a high-efficacy alternative with a clinically distinct mechanism and monitoring profile left neurologists and families with limited flexibility.

    How Ocrelizumab Works and Why B-Cell Depletion Matters in MS

    Ocrelizumab is a humanized anti-CD20 monoclonal antibody. CD20 is a surface protein expressed on B cells throughout most of their development, from pre-B cells through mature B cells, but not on plasma cells or hematopoietic stem cells. When ocrelizumab binds CD20, it triggers B-cell depletion through three mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction.

    The role of B cells in MS pathogenesis has been substantially clarified in the decade since ocrelizumab’s original approval. B cells contribute to MS inflammation not just as antibody-producing cells but as antigen-presenting cells that activate CD4+ and CD8+ T cells, as producers of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and as modulators of the inflammatory microenvironment within CNS lesions. Depleting B cells interrupts these multiple contributions to disease activity, producing the robust efficacy on both relapse rates and MRI lesion accumulation that has made ocrelizumab one of the most effective MS therapies in adult practice.

    In the pediatric setting, ocrelizumab’s mechanism offers specific theoretical advantages: because POMS is characterized by highly active inflammatory disease, the near-complete B-cell depletion produced by ocrelizumab (blood B-cell counts typically fall to undetectable levels within 2 weeks of the first infusion and remain suppressed for the 24-week dosing interval) may be particularly well-matched to the disease biology. The OPERETTA 2 data tests this hypothesis directly.

    The OPERETTA 2 Trial: Full Results

    Design

    OPERETTA 2 (NCT05123703) was a randomized, double-blind, double-dummy, multicenter Phase 3 noninferiority trial. The double-dummy design means that all patients received both an IV infusion and an oral daily capsule, with one being the active drug and the other a matching placebo, ensuring neither patients nor investigators knew which treatment was assigned.

    The trial enrolled 187 pediatric patients aged 10 to 17 years with RRMS, randomized 1:1 to:

    • Ocrelizumab 600 mg intravenous infusion every 24 weeks, plus oral placebo daily (n approximately 94)
    • Fingolimod 0.5 mg oral capsule daily, plus intravenous placebo infusion every 24 weeks (n approximately 93)

    OPERETTA 2 was designed to demonstrate non-inferiority of ocrelizumab to fingolimod. The dose of ocrelizumab (600 mg every 24 weeks) is the same as the approved adult dose, a decision supported by pharmacokinetic and pharmacodynamic data from the companion OPERETTA 1 study that characterized ocrelizumab’s PK profile in the pediatric age range and confirmed that the adult dose produces comparable drug exposure in children aged 10 and older weighing at least 25 kg.

    Primary endpoint

    OutcomeOcrelizumabFingolimodComparison
    Annualized relapse rate (ARR)Significantly reducedReferenceNon-inferior (rate ratio 0.52; 95% CI 0.19 to 1.33)
    Primary non-inferiority endpointMetReferencep-value consistent with non-inferiority

    MRI endpoints (superiority)

    MRI OutcomeOcrelizumabFingolimodComparison
    New or enlarging T2 hyperintense lesions per MRI scan3.7787.235Relative reduction 47.8%; p=0.001
    Mean T1 gadolinium-enhancing lesions at week 120.0310.243Relative reduction 87.2%; p=0.001

    Source: OPERETTA 2 trial, NCT05123703. Genentech/FDA press release, May 8, 2026. Presented at AAN 2026 and published in advance of peer-reviewed journal publication.

    Interpreting the results

    The primary non-inferiority finding means ocrelizumab reduced annualized relapse rates in a manner that was statistically no worse than fingolimod, the current standard of care for this population. The 95% confidence interval for the rate ratio (0.19 to 1.33) is wide, reflecting the challenge of powering pediatric trials with small populations, but the point estimate (0.52) suggests that relapses were approximately 48% less frequent with ocrelizumab, a numerically superior result that did not reach formal superiority on the relapse endpoint.

    The MRI superiority findings are the more clinically discriminating results. A 48% reduction in new or enlarging T2 lesions and an 87% reduction in gadolinium-enhancing lesions versus fingolimod at week 12 are substantial advantages on the imaging markers that most directly reflect ongoing inflammatory disease activity. These MRI findings align with what was observed in adult comparisons of ocrelizumab versus other MS therapies: the anti-CD20 mechanism produces particularly deep suppression of new lesion formation, which correlates with long-term disability protection in adult studies.

    Safety in OPERETTA 2

    The safety profile of ocrelizumab in pediatric patients in OPERETTA 2 was consistent with its well-established nine-year adult safety record. The most commonly reported adverse events were infusion reactions, infections, and decreases in immunoglobulin levels, identical in type to what is documented in adult trials.

    Notably, no adverse events led to treatment withdrawal in the ocrelizumab arm during the double-blind period. This finding on discontinuation due to adverse events is clinically meaningful given that tolerability-driven discontinuation is one of the practical challenges of fingolimod’s first-dose cardiac monitoring requirement and ongoing ophthalmologic surveillance.

    MSBase Registry real-world data presented at the 2026 CMSC Annual Meeting further supports the OPERETTA 2 findings: an analysis of pediatric-onset MS patients in the registry showed that ocrelizumab maintained similar effectiveness and safety in pediatric-onset disease compared to young-adult onset disease, providing external validation from clinical practice in countries where ocrelizumab has been used off-label or under compassionate access in pediatric patients.

    Ocrevus’s Full Approved Indication Picture After May 2026

    With the pediatric RRMS approval, Ocrevus now carries the following FDA-approved indications:

    IndicationPopulationApproval date
    Relapsing forms of MS (CIS, RRMS, active SPMS)AdultsMarch 2017
    Primary progressive MSAdultsMarch 2017
    RRMSPediatric patients aged 10 years and older weighing at least 25 kgMay 8, 2026

    Ocrevus also has a subcutaneous formulation, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), approved in September 2024 for adults, which delivers the same dose subcutaneously in 10 minutes rather than the 3.5-hour intravenous infusion. The subcutaneous formulation is currently approved for adults only; the pediatric indication uses the intravenous formulation.

    Safety Considerations for the Pediatric Population

    The safety profile of ocrelizumab is well-established from more than nine years of adult use and now confirmed in OPERETTA 2 for the pediatric setting. Key considerations for parents and pediatric neurologists:

    Infusion reactions: The most common adverse event during ocrelizumab treatment is infusion-related reactions occurring during or within 24 hours of infusion. Pre-medication with corticosteroids, antihistamines, and analgesics is administered before each infusion per protocol. These reactions are typically mild to moderate and manageable.

    Infections: Because B-cell depletion reduces one component of humoral immunity, patients on ocrelizumab are at modestly increased risk of respiratory infections, particularly upper respiratory tract infections. Serious infections occurred at low rates in both adult and pediatric trials. Opportunistic infections including PML (caused by JC virus) have been reported rarely in adult patients, primarily in those with additional immunocompromising factors.

    Decreasing immunoglobulins: Long-term B-cell depletion leads to gradual decline in IgG and IgM levels over years of treatment. Monitor immunoglobulin levels periodically. Significant hypogammaglobulinemia may require dose adjustment or management in some patients.

    Vaccinations: Live vaccines should not be administered during treatment or until B cells have reconstituted after stopping treatment. All recommended immunizations should be completed before initiating Ocrevus. This is particularly important in the pediatric setting where routine childhood vaccination schedules need to be coordinated with treatment initiation.

    PML risk: Ocrevus carries a boxed warning for progressive multifocal leukoencephalopathy (PML), though the absolute risk appears substantially lower than with natalizumab (Tysabri). No cases of PML were reported in OPERETTA 2.

    Dosing and Administration for Pediatric Patients

    ParameterDetails
    Approved dose (ages 10 and older, weight at least 25 kg)600 mg IV every 24 weeks
    First doseTwo 300 mg infusions given 2 weeks apart
    Subsequent dosesSingle 600 mg infusion every 24 weeks
    Pre-medication requiredMethylprednisolone (or equivalent corticosteroid) IV, antihistamine, and optional antipyretic before each infusion
    Infusion duration (600 mg)Approximately 3.5 hours
    SettingHealthcare facility with emergency equipment and resuscitation capability available
    Weight requirementAt least 25 kg (approximately 55 lbs)
    Age lower limit10 years and older
    Not forChildren under 10 years of age or weighing less than 25 kg

    What This Approval Means for Families and Pediatric Neurologists

    For families of children with RRMS

    For the first time, a family whose child has RRMS has a choice between two FDA-approved treatment options rather than only one. Ocrevus, administered every six months as an intravenous infusion, offers a different monitoring profile, mechanism of action, and efficacy signal than daily oral fingolimod.

    Practical considerations for families when discussing this option with your child’s neurologist:

    • Ocrevus is infused twice a year. Fingolimod is taken daily. For some families, twice-yearly clinic visits for infusion are more manageable than ensuring daily adherence; for others, the infusion schedule is a barrier.
    • The first-dose cardiac monitoring requirement with fingolimod is not required with Ocrevus.
    • The ophthalmologic monitoring required with fingolimod is not required with Ocrevus.
    • The 87% reduction in gadolinium-enhancing lesions at week 12 versus fingolimod in OPERETTA 2 indicates a measurably deeper suppression of active inflammation with Ocrevus in the pediatric trial.
    • All immunizations should be current and any live vaccines completed before starting Ocrevus. This timing requires planning with your child’s pediatrician and neurologist.

    For pediatric neurologists

    OPERETTA 2 provides the first randomized head-to-head controlled evidence comparing a high-efficacy anti-CD20 therapy to fingolimod in pediatric RRMS. The non-inferiority on ARR combined with superiority on both MRI endpoints justifies positioning ocrelizumab as a strong option for treatment-naive patients with active disease, not just as a step-up therapy after fingolimod failure.

    The absence of treatment withdrawal due to adverse events in the ocrelizumab arm is a meaningful tolerability signal in a population where treatment persistence over years and decades is the goal. Monitoring requirements for ocrelizumab are primarily infusion reaction surveillance, immunoglobulin levels, and standard infection monitoring, rather than the cardiac and ophthalmologic monitoring that fingolimod requires.

    The American Academy of Neurology and the International Pediatric MS Study Group will be updating their guidance frameworks in response to this approval. The National MS Society’s healthcare providers section provides updated clinical resources.

    For families: the National MS Society and Can Do MS both maintain dedicated pediatric MS resources. The International Pediatric MS Study Group connects families with specialized clinical expertise.

    For related HED coverage of other neurological condition approvals and anti-CD20 therapy advances in 2026, see our post on Fasenra (benralizumab) approved for hypereosinophilic syndrome as another example of a biologic agent expanding from adult to pediatric and rare disease settings, and our post on VYVGART and the first approval covering all forms of myasthenia gravis.

    Sources

    FDA approval announcement: FDA approves ocrelizumab for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. FDA.gov. May 8, 2026.

    Genentech press release: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis in Pediatric Patients 10 Years of Age and Older. gene.com. May 8, 2026.

    Drugs.com approval news: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age and Older. drugs.com. May 2026.

    NeurologyLive clinical summary: FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. neurologylive.com. May 2026.

    Neurology Advisor detailed coverage: Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis. neurologyadvisor.com. May 2026.

    Pharmacy Times clinical review: FDA Approves Ocrelizumab for Pediatric Relapsing-Remitting Multiple Sclerosis. pharmacytimes.com. May 2026.

    Medscape coverage: FDA Approves Ocrelizumab for Pediatric Relapsing MS. medscape.com. May 2026.

    MS News Today coverage: In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS. multiplesclerosisnewstoday.com. May 2026.

    CMSC 2026 real-world data: CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. neurologylive.com. May 2026.

    Practical Neurology: FDA Approves Ocrevus for Pediatric Relapsing-Remitting MS. practicalneurology.com. May 2026.

    OPERETTA 2 trial registration: NCT05123703. ClinicalTrials.gov.

    Ocrevus original FDA approval: FDA approves ocrelizumab for multiple sclerosis. FDA.gov. March 2017.

    Fingolimod pediatric approval: FDA approves fingolimod for pediatric patients with multiple sclerosis. FDA.gov. 2018.

    Ocrevus prescribing information: OCREVUS (ocrelizumab) Prescribing Information. Genentech. 2026.

    Ocrelizumab mechanism review: CD20-directed B-cell depleting therapies in MS. PMC6369883.

    Pediatric MS StatPearls: Pediatric Multiple Sclerosis. StatPearls. NCBI.

    Pediatric MS cognitive effects: Cognitive Impairment in Pediatric Multiple Sclerosis. PMC7897219.

    ADCC mechanism: Antibody-Dependent Cell-Mediated Cytotoxicity. StatPearls. NCBI.

    National MS Society pediatric resources: Pediatric MS. nationalmssociety.org.

    Patient resources: National MS Society: Pediatric MS | International Pediatric MS Study Group | Can Do MS | American Academy of Neurology

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about MS treatment, including the choice of disease-modifying therapy for pediatric patients, should be made in close consultation with a pediatric neurologist or MS specialist experienced in pediatric-onset multiple sclerosis.

healthevidencedigest